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ABSTRACT
Jensen, Brock Thomas. The Effect of Exercise on Cardiac Function and Doxorubicin
Accumulation in Left Ventricular Tissue of Rats Published Doctor of Philosophy
Dissertation, University of Northern Colorado, 2011.

Doxorubicin (DOX) is an anthracycline antibiotic that has cytotoxic actions. The
therapeutic use of DOX to treat a wide array of cancers is limited by a dose-dependent
cardiotoxicity. Although DOX is known to have several adverse side-effects, acute and
chronic cardiotoxicity have received the most attention as both may eventually lead to
heart failure. While exercise has been shown to protect against DOX cardiotoxicity, a
clear and consistent mechanism to explain its cardioprotective effects is lacking. High
performance liquid chromatography (HPLC) is a valuable instrument that can be used to
evaluate cardiac DOX accumulation. We hypothesized that a reduction in cardiac DOX
accumulation may be a mechanism of exercise-induced cardioprotection. Therefore, the
purpose of this study was to determine if exercise preconditioning reduces cardiac DOX
accumulation, thereby providing a possible mechanism to explain the cardioprotective
effects of exercise against DOX toxicity. Female Sprague-Dawley rats were randomly
assigned to 1 of 3 primary experimental groups: sedentary (SED), voluntary wheel
running (WR) or treadmill (TM). Animals in WR and TM groups completed 10 weeks of
exercise prior to DOX treatment. DOX was administered 24 hours after the last training
session as a bolus i.p. injection at 10 mg/kg. Subgroups of rats from each primary group
were sacrificed at 1, 3, 5, 7, and 9 days post exposure and cardiac function was analyzed.
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Twenty-four hours following sacrifice, cardiac DOX accumulation was analyzed using
HPLC. DOX treatment resulted in both in vivo and ex vivo cardiac dysfunction.
However, 10 weeks of either involuntary or voluntary exercise preconditioning preserved
cardiac function. Additionally, significant differences were observed between sedentary
and exercise groups for DOX accumulation. The greatest accumulation of DOX was
observed in SED+DOX 1 day post injection. When compared to SED+DOX (day 1),
DOX accumulation in TM+DOX (day 1) and WR+DOX (day 1) groups was significantly
reduced (p < 0.05). Similarly, DOX accumulation in SED+DOX at both 3 and 5 days
was significantly greater than both TM+DOX and WR+DOX at 3 and 5 days,
respectively (p < 0.05). DOX accumulation in TM+DOX and WR+DOX groups was
non-existent at both 7 and 9 days. Because DOX accumulation remained elevated in
SED+DOX at 7 days, it was significantly greater than TM+DOX and WR+DOX groups
(p < 0.05). Therefore, it is possible that the cardioprotective effects of exercise against
acute DOX-induced injury may be due, in part, to a reduction in myocardial DOX
accumulation.
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CHAPTER I
INTRODUCTION
Epidemiological research over the last decade suggests that cancer incidence and
death rates for all cancers combined are decreasing mainly as a result of advances in early
detection and improved therapeutic strategies (National Cancer Institute, 2009).
Chemotherapy is commonly used for the treatment of disease via chemicals that either
have a specific toxic effect upon disease-producing microorganisms or selectively destroy
cancer cells. The most common chemotherapeutic anthracycline used clinically is
doxorubicin (DOX; trade name Adriamycin). In 1974, clinicians started prescribing
DOX to cancer patients as a chemotherapy treatment (Minotti, Menna, Salvatorelli,
Cairo, & Gianni, 2004; Weiss, 1992). While the antineoplastic activity of DOX is
evident, the exact mechanisms are unknown. It is hypothesized that DOX causes
deoxyribonucleic acid (DNA) biosynthesis inhibition (Gewirtz, 1999), apoptosis
(Clementi, Giardina, Di Stasio, Mordente, & Misiti, 2003), and free radical-mediated
cellular injury (Minotti, Menna, et al., 2004). Despite its effective antineoplastic
properties, the administration of DOX is limited as a result of its relatively high rate of
dose-dependent cardiotoxicity (Jain, 2000).
DOX-induced cardiotoxicity is characterized by acute cardiac injury that may
progress to irreversible cardiomyopathy and congestive heart failure months to years
following treatment (Singal & Iliskovic, 1998; Singal, Li, Kumar, Danelisen, & Iliskovic,
2000). The exact mechanisms of DOX mediated cardiotoxicity are unknown; however,
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oxidative stress appears to be the largest contributor. The C-ring of DOX undergoes
heavy redox cycling in cardiomyocytes. The DOX quinone moiety oxidizes nicotinamide
adenine dinucleotide dehydrogenase oxidoreductase (NADH) to form a semiquinone. In
an attempt to reform the quinone, oxygen (O2) is immediately reduced and reactive
oxygen species (ROS) such as superoxide anion (O2 .-) and hydrogen peroxide (H2O2) are
formed (Minotti, Menna, et al., 2004).
Several studies suggest that chronic exercise training prior to DOX treatment
attenuates DOX-induced cardiotoxicity (Chicco, Schneider, & Hayward, 2005, 2006;
Hydock, Lien, Schneider, & Hayward, 2008; Wonders, Hydock, Greufe, Schneider, &
Hayward, 2009). Additionally, recent research indicates that acute and short-term
exercise is cardioprotective against DOX-mediated cardiac dysfunction (Jensen, et al.,
2009; Jensen, Hydock, Lien, Schneider, & Hayward, 2008; Lien, Hydock, Jensen,
Schneider, & Hayward, 2009; Wonders, Hydock, Schneider, & Hayward, 2008). The
mechanisms associated with exercise-induced cardioprotection against DOX
cardiotoxicity are not fully understood. However, exercise may protect cardiac tissue
from DOX-induced dysfunction by increasing antioxidative enzyme activity and
expression (Ascensao, Magalhaes, Soares, et al., 2005; Chicco, Hydock, Schneider, &
Hayward, 2006), decreasing lipid peroxidation (Ascensao, Magalhaes, et al., 2005a;
Ascensao, Magalhaes, et al., 2005b; Chicco, Schneider, et al., 2006; Wonders, et al.,
2009), upregulating heat shock protein 72 (HSP72) (Chicco, et al., 2005), preserving
myosin heavy chain (MHC) isoform distribution (Hydock, Lien, Jensen, et al., 2009;
Hydock, et al., 2008; Jensen, et al., 2009; Lien, et al., 2009), or downregulating
proapoptotic enzymes (Wonders, et al., 2009). Additionally, a recent pilot study by our
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laboratory using high performance liquid chromatography (HPLC) has shown that less
DOX accumulates in cardiac tissue of exercised rats when compared to sedentary rats
(Bradshaw, Karnilaw, Hayward, & Hyslop, 2009). Thus the cardioprotective effects of
exercise may be due, at least in part, to a difference in the accumulation of DOX in the
heart.
Since both short-term and chronic exercise preconditioning are cardioprotective in
rats receiving DOX, it is hypothesized that DOX accumulation would be reduced in
exercise preconditioned rats when compared to their sedentary counterparts. One
possible explanation for a reduction in DOX accumulation could be an increased
expression of multidrug resistance associated proteins (MRPs). Cancer cells express
MRPs, which are glycoproteins capable of antitumor agent translocation (Krause, et al.,
2007). DOX that is introduced to cancerous cells can initiate apoptosis or necrosis;
however, when MRPs are expressed, DOX is extruded from the cell thereby preventing
its accumulation inside the cell. The result is a decrease in DOX accumulation and an
increased likelihood of tumor proliferation. If MRPs are upregulated in cardiomyocytes
of exercised animals, these cardiac cells may accumulate less DOX (Krause, et al., 2007)
thereby providing a theoretical basis for exercise-induced cardioprotection against DOX
toxicity.
Statement of Purpose
The purpose of this study was two-fold: (a) to investigate the effects of chronic
exercise preconditioning on cardiac DOX accumulation and to what extent it is related to
DOX induced cardiac dysfunction, and (b) to apply an HPLC based method for a time-
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course determination of DOX clearance in a complex biological sample matrix (rat left
ventricular tissue).
Research Hypotheses
H1

Detectable quantities of DOX from left ventricular tissue will decrease as
time elapses following DOX exposure.

H2

Chronic exercise trained animals will have less DOX accumulation in left
ventricular tissue when compared to sedentary animals throughout a 9-day
observation period.

H3

Chronic exercise before DOX treatment will preserve cardiac function,
and this will be related to a decline in DOX accumulation in the hearts of
exercised animals.
Need for the Study

Cancer survivorship has improved in recent decades, however, toxicity associated
with some of the most effective chemotherapeutic antibiotics still exists. One of the most
widely used antineoplastic agents is DOX (Jain, 2000). DOX is used in the treatment of
several cancers, however, it is associated with a dose-dependent cardiotoxicity that can
eventually progress to heart failure (Singal & Iliskovic, 1998). Doxorubicin
cardiotoxicity is characterized by acute cardiac injury that may progress to irreversible
cardiomyopathy and congestive heart failure months to years following treatment
(Ferrans, Clark, Zhang, Yu, & Herman, 1997). However, exercise training can offer
protection against a variety of acute and chronic myocardial injuries (Ascensao,
Magalhaes, Soares, Ferreira, Neuparth, Appell, et al., 2005). It has been shown that
exercise preconditions the myocardium so that it is protected against oxidative stress by
increasing antioxidative enzyme activity and expression, increasing heat shock protein
content, preserving MHC, and possibly reducing the accumulation of DOX in
cardiomyocytes. Less DOX accumulation in rat myocardia may reduce the various forms
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of injury to cardiac tissue, and this adaptation may protect the hearts of preconditioned
rats against cardiac dysfunction and injury induced by DOX treatment. Currently, there
are no studies that have examined the effectiveness of exercise training on cardiac DOX
accumulation. Therefore, this investigation is focused on the use of exercise to attenuate
cardiac DOX accumulation and cardiac dysfunction associated with DOX treatment.
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Table 1
Abbreviations.
ABC - ATP binding cassette
AFC - affinity chromatography
AIF - apoptosis-inducing factor
ATP - adenosine triphosphate
Ca++ - calcium
CAT - catalase
CO - cardiac output
DNA - deoxyribonucleic acid
DAUN - daunorubicin
DOX - doxorubicin
DOX-ol - doxorubicinol
dP/dtmax - maximum rate of developed pressure
dP/dtmin - minimum rate of developed pressure
EDP - end diastolic pressure
EPI - epirubicin
EPIDAUN - epidaunorubicin
ESP - end systolic pressure
ET - ejection time of aortic blood flow
ERK - extracellular signal-regulated kinases
Fe2+/Fe3+ - iron
FS - fractional shortening
GPx - glutathione peroxidase
HPLC - high performance liquid chromatography
HR - heart rate
HSPs - heat shock proteins
HSP70 - heat shock protein 70
HSP72 - heat shock protein 72
H2O2 - hydrogen peroxide
IDA - idarubicin
IEC - ion exchange chromatography
i.p. - intraperitoneal
i.v. - intravenous
LV - left ventricle
LVDd - LV end diastolic diameter
LVDP - LV developed pressure
LVDs - LV end systlic diameter

LVDPd - LVDP during diastole
LVDs - LV end systolic diameter
LVEDV - LV end diastolic volume
LVESV - LV end systolic volume
MDR - multidrug resistance proteins
MHC - myosin heavy chain
MPT - membrane permeability transition
MPTP - membrane permeability transitional pore
MRPs - multidrug resistance associated proteins
mtDNA - mitochondrial DNA
NADH - nicotinamide adenine dinucleotide dehydrogenase
oxidoreductase
NO - nitric oxide
ONOO- - peroxynitrite
O2 - oxygen
O2 .- - superoxide anion
·OH - hydroxyl radical
PWd - posterior wall thickness during diastole
PWs - posterior wall thickness during systole
ROS - reactive oxygen species
RONS - reactive oxygen and nitrogen species
RPLC - reversed phase liquid chromatography
RWT - relative wall thickness
SEC - size exclusion chromatography
SED - sedentary
SOD - superoxide dismutase
SV - stroke volume
SWd - septal wall thickness during diastole
SWs - septal wall thickness during systole
TM - treadmill
A-Vmax - maximal aortic flow velocity
A-Vmean - mean aortic flow velocity
M-Vmax - maximal mitral flow velocity
M-Vmean - mean mitral flow velocity
VTI - velocity time integral
WR - voluntary wheel running
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Delimitation of the Study
Samples in this study included 10-11 week old female Sprague-Dawley rats (180210 g). Cardiotoxicity was induced using a 10 mg/kg bolus intraperitoneal (i.p.) injection
of DOX. The exercise training groups ran on a motorized treadmill at 30 m/min up an
18% grade for 60 minutes, 5 days a week for 10 weeks.
Definition of Terms
Apoptosis - programmed cell death.
Cardiolipin - obligatory phospholipids localized to the inner mitochondrial
membrane, responsible for maintenance of the structure and metabolic function of the
mitochondria membrane proteins.
Cardioprotection - adaptations in the heart that provide increased tolerance to
ischemic or chemical induced injury.
DOX-induced cardiotoxicity - development of cardiac abnormalities following the
exposure to DOX.
Echocardiogram - an ultrasonic technique used to image real-time cardiac tissue
dimensions and blood flow velocities.
High performance liquid chromatography - a form of column chromatography
used frequently in biochemistry and analytical chemistry to separate, identify and
quantify compounds. HPLC can utilize a column that holds chromatographic packing
material, a pump that moves the mobile phase through the column, and a detector that
shows the retention times of molecules such as DOX.
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MHC - an abundant contractile protein. The ATPase associated with each MHC
hydrolyzes ATP. In cardiomyocytes, there are two MHC isoforms (α and β). The αMHC has faster ATPase activity in comparison to β-MHC.
M-mode - An imagining mode used to determine cardiac geometry during
echocardiography.
Multidrug resistant proteins - proteins found in cellular membranes responsible
for the efflux of xenobiotics.
Membrane permeable transitional pores - protein pore formed in the
mitochondrial membrane under stress induced conditions. When induced, it contributes
to mitochondrial swelling, dysfunction, and cellular apoptosis.
Mitochondrial dysfunction - the impairment of function or abnormalities observed
exclusively in the mitochondria. The dysfunction is primarily due to the adverse effects
of drugs, infections, or other environmental causes.
Necrosis - the premature death of living cells and tissue.
Xenobiotic - a chemical neither expected to be found in an organism nor naturally
synthesized.
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CHAPTER II
REVIEW OF LITERATURE
Introduction
Anthracyclines are a specific group of antineoplastic drugs known to have the
widest range of clinical use of any class of drugs in oncology (Minotti, Menna, et al.,
2004). The anthracyclines are highly effective anticancer antibiotics used in the
treatment of a variety of malignancies. Of the anthracyclines, DOX, is the most effective
and has the greatest range of treatment, however, its use is limited clinically by a dosedependent cardiotoxicity which may eventually lead to heart failure (Lipshultz, et al.,
2005; Singal, et al., 2000). The acute form of cardiotoxicity often develops within a short
period of time following DOX treatment (Ferrans, et al., 1997; Tokarska-Schlattner,
Zaugg, Zuppinger, Wallimann, & Schlattner, 2006). Numerous molecular mechanisms
for DOX cardiotoxicity have been hypothesized (Minotti, Menna, et al., 2004; Zucchi &
Danesi, 2003), however, oxidative stress (Krause, et al., 2007; Schimmel, Richel, van den
Brink, & Guchelaar, 2004), mitochondrial dysfunction (Zhou, Starkov, Froberg, Leino, &
Wallace, 2001) and apoptosis (Minotti, Menna, et al., 2004) appear to be the largest
contributors.
Results from animal studies indicate that chronic exercise training (Chicco,
Hydock, et al., 2006; Chicco, et al., 2005; Chicco, Schneider, et al., 2006; Hydock, et al.,
2008; Wonders, et al., 2009) and short-term exercise (Jensen, et al., 2009; Jensen, et al.,
2008; Wonders, et al., 2008) can attenuate DOX-mediated cardiotoxicity. DOX
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treatment leads to impairment in both in vivo (Hydock, Lien, & Hayward, 2009; Hydock,
et al., 2008) and ex vivo (Hydock, Wonders, Schneider, & Hayward, 2009; Wonders, et
al., 2009) cardiac function. It has been demonstrated that exercise protects against DOXinduced cardiac dysfunction by preserving end systolic pressure (ESP), end diastolic
pressure (EDP), left ventricular developed pressure (LVDP), maximum rate of developed
pressure (dP/dtmax), and minimum rate of developed pressure (dP/dtmin) (Hydock, et al.,
2008; Jensen, et al., 2008; Wonders, et al., 2009; Wonders, et al., 2008). The
mechanisms by which exercise offers protection from myocardial injury are not fully
understood; however, an increase in antioxidative capacity (Ascensao, Magalhaes,
Soares, et al., 2005; Chicco, Hydock, et al., 2006) appears to play an important role.
In order to directly study cardioprotective cellular mechanisms, many instruments
and techniques have been used. One such method is chromatography, a physical
separation of components in a mixture of compounds (Loadman & Calabrese, 2001;
Wang, Mallette, & Parcher, 2008). Bradshaw et al. (2009) assert that HPLC is useful for
quantifying DOX accumulation in experiments with sedentary and exercise
preconditioned rats.
The purpose of this study was to investigate the effects of chronic exercise
preconditioning on cardiac DOX accumulation and its relationship to DOX-induced
cardiac dysfunction. An additional purpose of this investigation was to apply an HPLCbased method for a time-course determination of DOX accumulation in a complex
biological sample matrix.
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Doxorubicin
Daunorubicin (DAUN) and DOX are among the most effective and commonly
prescribed antineoplastic chemotherapeutic agents (Weiss, 1992). In 1963, researchers’
derived DAUN from Streptomyces peucetius. Shortly after its discovery, DAUN was
used clinically to treat myeloblastic leukemias (Weiss, 1992). Over a decade later, DOX,
a 14-hydroxy analog of DAUN, was clinically prescribed to cancer patients in the United
States for the treatment of childhood tumors, lymphomas, and breast cancer (Minotti,
Menna, et al., 2004). To date, there are over 2000 antrhacycline analogs; however
DAUN, DOX, epirubicin (EPI), and idarubicin (IDA) are the most clinically relevant.
Despite the common use of DOX, the antineoplastic mechanisms are not fully
understood. The primary antitumor mechanism of DOX is hypothesized to involve DNA
intercalation. DOX inhibits DNA biosynthesis by migrating into cells via simple
diffusion and binding to proteosomes in the cytoplasm, thereby forming a DOXproteasome complex that can cross the nuclear membrane. Upon dissociation of the
proteasome, DOX binds to DNA. Consequently, DOX stimulates double-stranded DNA
scission and inhibits topoisomerase activity which prevents DNA replication in the cell
(Cummings, Anderson, Willmott, & Smyth, 1991; Gewirtz, 1999; Lothstein, et al., 2000).
Furthermore, the antineoplastic effects of DOX may in part be attributed to cytotoxic free
radicals induced by DOX (Minotti, Menna, et al., 2004). Free radicals are responsible for
events leading to lipid peroxidation, DNA damage and apoptosis; however, their role is
more predominantly involved in DOX-mediated cardiotoxicity.
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Doxorubicin Cardiotoxicity
The utilization of DOX is limited due to acute and chronic cardiotoxicity. DOX
cardiotoxicity is characterized by acute cardiac injury that may progress to irreversible
cardiomyopathy and congestive heart failure months to years following treatment (Singal
& Iliskovic, 1998; Singal, et al., 2000). The acute form of cardiotoxicity often develops
within minutes, hours, or days following DOX treatment (Ferrans, et al., 1997; TokarskaSchlattner, et al., 2006). Cardiac arrhythmias, pericarditis, hypotension, myofibrillar
disorganization, cardiomyocyte vacuolization, and elevated serum enzyme markers are
all signs of acute cardiotoxicity (Abdel-Wahab, et al., 2003; Ferrans, et al., 1997; Lefrak,
Pitha, Rosenheim, & Gottlieb, 1973; Mihm, Yu, Weinstein, Reiser, & Bauer, 2002;
Parry, et al., 2009; Schimmel, et al., 2004; Singal & Iliskovic, 1998). Even though the
early signs of cardiac dysfunction are reversible, acute toxicities associated with DOX are
highly predictive of chronic toxicities (Cardinale, et al., 2002; Nousiainen, Jantunen,
Vanninen, & Hartikainen, 2002).
Chronic DOX cardiotoxicity may present months, years, or decades after DOX
has been cleared from the body. DOX cardiotoxicity is responsible for structural changes
of the myocardia which may lead to functional changes. Decreased cardiac function due
to DOX cardiotoxicity (indicated by a reduction in left ventricular ejection fraction)
(Ferrans, et al., 1997), is often caused by dilated cardiomyopathy (Singal & Iliskovic,
1998), which may eventually lead to congestive heart failure and dysrhythmias years
following exposure to DOX (Steinherz, Steinherz, Tan, Heller, & Murphy, 1991).
Approximately 5% of patients who receive a 550 mg/m2 commutative dose of DOX will
develop dilated cardiomyopathy within 4-20 years (Steinherz, et al., 1991). This
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percentage increases when higher doses are administered (Singal, Iliskovic, Li, & Kumar,
1997).
Mechanisms of Doxorubicin Cardiotoxicity
Oxidative Stress
The exact mechanisms of DOX mediated cardiotoxicity are unknown; however,
oxidative stress appears to be the largest contributor. The production of excessive
quantities of reactive oxygen and nitrogen species (RONS) is an important mechanism of
DOX-induced cardiotoxicity. The C-ring of DOX undergoes redox cycling in
cardiomyocytes. The DOX quinone moiety oxidizes NADH to form a semiquinone. In
an attempt to reform the quinone, O2 is immediately reduced and ROS such as O2.- and
H2O2 are formed (Minotti, Menna, et al., 2004). O2.- is a potent free radical that can
injure cardiomyocytes. In the presence of the antioxidant enzyme, superoxide dismutase
(SOD), O2.- can undergo dismutation in which O2.- is converted to hydrogen peroxide
H2O2. If O2.- is not converted to H2O2, it may combine with nitric oxide (NO) to form
peroxynitrite (ONOO-), a powerful nitrogen oxygen species known to affect key proteins
in myocardial tissue (McCord, 1985). Glutathione peroxidase (GPx) or catalase (CAT),
two antioxidant enzymes located in cardiomyocytes, can convert H2O2 into water.
However, if H2O2 is not converted to water, it may react with iron (Fe²+/Fe³+) to form a
hydroxyl radical (·OH), which is known to be the most potent free radical produced and
has a greater cellular toxicity than O2·- (Muindi, Sinha, Gianni, & Myers, 1984).
Therefore, RONS induced by the redox cycling of DOX may further exacerbate cardiac
dysfunction.
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Mitochondrial Dysfunction
Mitochondria play a key role in cardiac cell survival and death. They are
essential for adenosine triphosphate (ATP) production, regulation of intracellular calcium
(Ca++) homeostasis, and the main generators of intracellular ROS (Zhou, et al., 2001).
Damage to the mitochondrial membranes may result in the excessive production of ROS,
formation and dysfunction of membrane permeability transitional pores (MPTP), and a
release of apoptotic proteins. Therefore, mitochondria control many of the pathways that
lead to cellular death (Crompton, 1999; Singal, et al., 2000).
DOX exhibits a strong affinity for cardiolipin, an abundant and obligatory lipid
that is localized to the inner mitochondrial membrane (Cheneval, Muller, Toni, Ruetz, &
Carafoli, 1985; Goormaghtigh, Huart, Praet, Brasseur, & Ruysschaert, 1990; Yaroslavov,
et al., 2003). Cardiolipin when combined with DOX causes cytochrome c to be released,
decreasing both ATP production and inducing apoptosis. A recent report suggested that
DOX is capable of migrating beyond the membrane and penetrating the mitochondrial
matrix to directly interact with mitochondrial DNA (Ashley & Poulton, 2009b). This in
part, may explain the cardioselective mitochondrial toxicity of DOX. Additionally, the
large quantity of mitochondria in cardiomyocytes (approximately 30-35% of the total cell
volume), the cardiomyocyte demand of a continuous supply of ATP for contractile
purposes, and the abundance of ATP derived from oxidative metabolism all contribute to
the mitochondrial specificity of DOX and the deleterious effects on mitochondrial
bioenergetics (Carvalho, et al., 2010; Herman & Young, 1979; Tokarska-Schlattner, et
al., 2006).
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Several other mitochondrial structures and processes provide primary targets for
drug-induced toxicity and cell death (Starkov & Wallace, 2002). Lemasters and
colleagues (1998) reported that drug-induced oxidative injury caused pyridine nucleotide
oxidation, mitochondrial generation of RONS, and increased mitochondrial Ca++
concentrations, leading to an induction of MPTP. The theory behind MPTP induction is
that cytoxicity stimulates mitochondrial permeability transition (MPT). MPT is a
phenomenon whereby the controlled permeability of the inner mitochondrial membrane is
altered and the mitochondria are no longer selectively permeable to solutes such as Ca++;
thus leading to depolarization of the membrane and osmotic swelling (Crompton, 1999;
Kroemer & Reed, 2000; Lemasters, et al., 1998). It is hypothesized that the disruption of
the mitochondrial membrane due to the unnecessary depolarization of the membrane may
lead to the release of cytochrome c and other apoptogenic factors in the intermembrane
space, such as apoptosis-inducing factor (AIF), endonuclease G, and procaspase-9
(Crompton, 1999; Gillick & Crompton, 2008; Kroemer & Reed, 2000).
Mitochondrial dysfunction induced by MPT is linked to DOX cardiotoxicity.
MPT is a direct consequence of mitochondrial Ca++ overload, known to cause the
inhibition of ATP synthesis and the release of apoptotic factors (Gillick & Crompton,
2008; Lemasters, et al., 1998). Calcium enters the mitochondria electrophoretically and
is controlled by a transport cycle driven by the proton pumps of the respiratory chain.
Under physiological conditions mitochondrial Ca++ controls key metabolic regulatory
enzymes such as pyruvate dehydrogenase, oxoglutarate dehydrogenase, and isocitrate
dehydrogenase in the mitochondrial matrix. However, under conditions associated with
ATP depletion and oxidative stress, mitochondrial Ca++ stimulates the opening of MPTP,
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allowing more Ca++ to enter the matrix and inducing Ca++ overload which is known to be
an important factor in cellular injury (Crompton, 1999; Gillick & Crompton, 2008).
In DOX treated rats, the stimulation of mitochondrial calcium cycling is marked
by an increased sensitivity of cardiac mitochondria to calcium-induced membrane
depolarization (Sokolove & Shinaberry, 1988). The significance of increased sensitivity
to calcium is that the mitochondrial response to changing calcium concentrations is
compromised (Solem, Heller, & Wallace, 1996; Solem, Henry, & Wallace, 1994). Thus,
induction of MPTP by DOX results in an energy-consuming cyclical uptake and release
of calcium across the inner membrane, depolarization, reduced ATP, and eventually, cell
death. Mitochondrial dysfunction may also be the result of DOX’s ability to intercalate
mitochondrial DNA (mtDNA). Recently, Ashley et al., (2009a) reported that DOX and
other DNA intercalators, intercalated mtDNA within living cells and caused mtDNA
depletion. Therefore, DOX-mediated mitochondrial dysfunction does not appear to be
limited to oxidative stress (Ascensao, Magalhaes, Soares, et al., 2005), calcium
homeostasis (Solem, et al., 1994), or MPT induction (Crompton, 1999).
Exercise-Induced Cardioprotection
The benefits of chronic exercise training are well established. Endurance training
can improve cardiac function (Vella & Robergs, 2008) and is known to play an essential
role in the management of heart failure (Papathanasiou, Tsamis, Georgiadou, &
Adamopoulos, 2008), hypertension (Hansen, Nielsen, Saltin, & Hellsten, 2010),
hyperlipidemia (Wang, Hu, et al., 2009), hypercholesterolemia (Blake & Triplett, 1995),
and atherosclerosis (Kadoglou, Iliadis, & Liapis, 2008). Other physiological adaptations
that occur with endurance exercise include increased stroke volume (SV), decreased

17
resting heart rate (HR), and increased cardiac output (CO) which contributes to overall
improved cardiac function (Wilmore, et al., 2001). Exercise is also recognized for its role
in cardioprotection. Studies have been conducted using both chronic exercise training
(Chicco, Hydock, et al., 2006; Chicco, et al., 2005; Chicco, Schneider, et al., 2006;
French, et al., 2008; Hydock, et al., 2008; Quindry, et al., 2005; Wonders, et al., 2009)
and short-term exercise (Demirel, et al., 2001; French, et al., 2008; Hamilton, et al., 2001;
Wonders, et al., 2008) to limit the cardiac injury associated with ischemia and various
pharmacological agents. Several cellular mechanisms have been attributed to the
cardioprotective effects of exercise training. Many studies have reported that DOXmediated acute cardiotoxicity can be attenuated by an increase in myocardial antioxidant
capacity, HSP72 expression, α-MHC isoform, and DOX extrusion.
Increased Antioxidant Capacity
If RONS are not managed by myocardial antioxidants, enhanced production of
RONS results in several destructive processes in cardiomyocytes. Overexpression of a
free radical scavenger protein, metallothionein, is known to play a significant role in the
reduction of DOX-induced cardiotoxicity in transgenic mice (Kang, Chen, Yu, VossMcCowan, & Epstein, 1997; Naganuma, Satoh, & Imura, 1988; Satoh, Naganuma, &
Imura, 1988). Antioxidant enzymes such as SOD, CAT, and GPx are important proteins
found in cardiomyocytes, and when overexpressed in transgenic mice, the deleterious
effects of DOX are attenuated (Gouaze, et al., 2001; Kang, Chen, & Epstein, 1996; Yen,
Oberley, Vichitbandha, Ho, & St Clair, 1996). Additionally, it has been hypothesized
that increases in myocardial antioxidant capacity can be induced by exercise, contributing
to cardioprotection during periods of elevated oxidative stress (Ascensao, Magalhaes,
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Soares, et al., 2005; Atalay & Sen, 1999). Numerous studies have reported that exercise
increases the overall antioxidant capacity and it appears that increases in content (Siu,
Bryner, Martyn, & Alway, 2004) and/or activity (Chicco, et al., 2005; Gunduz, Senturk,
Kuru, Aktekin, & Aktekin, 2004; Husain, 2002, 2003; Husain & Somani, 1997; Kanter,
Hamlin, Unverferth, Davis, & Merola, 1985; Powers, et al., 1998) of SOD, CAT and GPx
in cardiac tissue are responsible for this adaptation.
In contrast to the aforementioned studies, a significant increase in myocardial
SOD, CAT, and/or GPx activities are not a requisite for exercise-induced
cardioprotection. Some studies have reported inconsistencies in the antioxidant adaptive
response to exercise (Atalay & Sen, 1999; Ji & Mitchell, 1994; Rinaldi, et al., 2006). Ji
and Mitchell (1994) reported that neither myocardial GPx nor CAT activities were altered
by exercise. Jensen et al., (2008) reported no statistical increase or preservation of SOD
and CAT activities in short-term preconditioned rats that received a 10 mg/kg bolus i.p.
injection of DOX, however, cardioprotection was still observed. Therefore, the role that
exercise plays in the regulation of the antioxidant system is complex in nature and
currently not fully understood.
Myocardial Heat Shock
Protein Expression
Heat shock proteins (HSPs) are known to play a key role in attenuating oxidative
injury in cardiomyocytes (Hamilton, et al., 2003; Starnes & Taylor, 2007). In models of
ischemia-reperfusion injury (Murlasits, Lee, & Powers, 2007; Quindry, et al., 2007) and
acute DOX cardiotoxicity (Chicco, et al., 2005; Chicco, Schneider, et al., 2006), exercise
induced an upregulation of HSP and offered cardioprotection in rats. HSPs are believed
to have protective effects by reducing oxidative injury, preventing the denaturing of key
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regulatory proteins, and reducing apoptosis and necrosis (Ascensao, Magalhaes, et al.,
2006; Powers, Quindry, & Hamilton, 2004). Animals that trained on a treadmill 5
days/wk up a 6% grade at 20 m/min for 60 min expressed a 12.3-fold increase in
myocardial HSP70 when compared to sedentary rats (Harris & Starnes, 2001). Similarly,
Chicco et al. (2005) reported that 8 weeks of voluntary wheel running led to an
upregulation of cardiac HSP72 expression and prevented cardiac dysfunction induced in
rats by the perfusion of 10 µM of DOX for 60 minutes. In another study by Chicco et al.
(2006), results suggested that DOX-induced cardiac dysfunction was attenuated by
increased cardiac expression of HSP72 in rats chronically trained for 12 weeks, when
compared to the SED+DOX animals. Furthermore, Murlasits et al. (2007) reported that
short-term exercise upregulated HSP72 and offered cardioprotection. Despite evidence
that suggests exercise induced HSP upregulation reduces cardiac injury, other reports
suggested cardioprotection is not necessarily due to an increase in myocardial HSP
expression (Starnes, Choilawala, Taylor, Nelson, & Delp, 2005), especially with shortterm exercise (Hamilton, et al., 2001; Jensen, et al., 2009; Taylor, Harris, & Starnes,
1999).
Myosin Heavy Chain
Isoform Distribution
MHC isoform distribution is known to influence cardiac function, and the
shifting of MHC isoforms can be significantly affected by DOX treatment (Hydock, et
al., 2008; Hydock, Wonders, et al., 2009). It was reported that 5 days post DOX
treatment, sedentary animals displayed a significant increase in the percentage of β-MHC
isoform, which contains the slower ATPase of the two isoforms. Exercise
preconditioning, however, attenuates this isoform shift (Hydock, et al., 2008).
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Additionally, rats that performed voluntary wheel running exercise while receiving DOX
expressed significantly higher levels of α-MHC isoform, the faster ATPase isoform,
when compared to their sedentary counterparts (Hydock, Wonders, et al., 2009).
Although a preservation of the MHC isoform distribution may not completely explain the
protective effects of exercise, it may be one of several adaptations that contribute to its
cardioprotective effects.
Doxorubicin Accumulation
Following the administration of anthracyclines such as DOX and EPI,
accumulation in cardiac tissue can occur very quickly (Buja, Ferrans, Mayer, Roberts, &
Henderson, 1973; Salvatorelli, Menna, Lusini, Covino, & Minotti, 2009; Urva, Shin,
Yang, & Balthasar, 2009). Timour et al. (1988) reported that intracellular concentrations
of DOX (4,000 ng/g) in canine myocardial cells, far exceeded plasma concentrations 3
hours after administration. Additionally, it was reported, following a 1.5 mg/kg
intravenous (i.v.) infusion of DOX, no detectable concentration was observed in plasma,
however, 200 ng/g was still detected in the myocardial tissue 1 week post-infusion. Little
is known regarding the accumulation of DOX in rat cardiac tissue. Recently, many
methods have been developed to quantify DOX in plasma, serum, and tissues (Ahmed, et
al., 2009; Maudens, Stove, Cocquyt, Denys, & Lambert, 2009; Urva, et al., 2009).
However, none of the reported methods have validated their findings with cardiac
function. Based on the proposed mechanisms of DOX cardiotoxicity, it may be possible
that a reduction in cardiac DOX accumulation could result in a reduced state of oxidative
stress, mtDNA interference, mitochondrial dysfunction and apoptosis. Furthermore, a
recent pilot study by our laboratory using HPLC has shown that less DOX accumulates in
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cardiac tissue of exercised rats when compared to sedentary controls (Bradshaw, et al.,
2009). Thus a cardioprotective effect of exercise may be the result of a difference in the
accumulation of DOX in the cardiac tissue of exercise trained rats.
Multidrug Resistance Proteins
A reduction in DOX accumulation may be the result of increased expression of
MRPs. MRPs are glycoproteins embedded in the cellular membrane which are
responsible for pumping xenobiotics out of the cell (Krause, et al., 2007; Patel, Dunn, &
Sorokin, 2002). These proteins belong to a superfamily of proteins known as ATP
binding cassette (ABC) transporters (Sorokin, 2004). Depending on location and tissue
type, MRPs can be further categorized into subgroups including: MRP-1, MRP-2, MRP3, MRP-4, MRP-5, MRP-6 and MRP-7. Studies have reported the expression of MRP-1,
MRP-2 (Rosati, et al., 2003) and MRP-5 (Dazert, et al., 2003; Meissner, et al., 2007) in
cardiac tissue. Additionally, the MRP-1/GS-X pumps have received attention due to their
potential role in DOX extrusion (Krause, et al., 2007). A theory was proposed by Krause
et al. (2007) which considered the possibility that DOX may be extruded via MRP-1/GSX pumps known to be expressed in cell membranes (de Bittencourt Junior, Curi, &
Williams, 1998) and suggested less DOX would reside in cardiomyocytes if MRP-1/GSX pumps were upregulated in cardiac cells. Furthermore, Krause et al. (2007) reported
rats that performed 60 minutes of swimming exercise for 1 week expressed a 2.4-fold
increase in myocardial MRP-1, when compared to their sedentary counter-parts;
however, DOX accumulation was not determined. Therefore, if MRPs are upregulated in
cardiomyocytes of exercised animals, cardiac cells may accumulate less DOX thereby
providing a theoretical basis for exercise-induced cardioprotection against DOX toxicity.
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High Performance
Liquid Chromatography
One purpose of this study was to determine the accumulation of DOX in rat
cardiac tissue as time elapses following DOX exposure using HPLC. Chromatography is
a method of physically separating the components in a mixture of compounds. This
technique provides information about the compounds general structures (polar
characteristics) (Korecka & Shaw, 2009; Zacharis, 2009). Specifically, liquid
chromatography can separate liquid samples by passing the sample over a solid
(stationary phase) with constant polarity. The stationary phase is composed of hydrated
silica gel (hydrocarbons). The hydrocarbons are polar and adhere to a steel column. A
liquid sample, when introduced to a liquid solvent, may be dissolved (mobile phase).
The mobile phase is responsible for wicking (wetting) the stationary phase. As the
solvent wicks the stationary phase, it interacts with the sample. The solvent dissolves the
sample due to the intermolecular attractions between the sample and the solvent. The
sample will also be attracted to the stationary phase. As the sample is dissolved in the
solvent, it moves down the column in a “zigzag path” (i.e. dissolved in the solvent,
absorbed on the stationary phase, dissolved in the solvent, absorbed on the stationary
phase, and so on). Different compounds will have different attractions for the solvent and
for the stationary phase, thus they will move down the stationary phase at different rates.
It is in this process that separation occurs. The effectiveness of separating a complex
sample mixture depends on the “zigzag” frequency (Gooding & Regnier, 2002).
The extent of sample separation is proportional to the total surface area, therefore,
if the stationary phase has a greater surface area, the components of a mixture have more
opportunity to interact with the stationary phase. In HPLC, the stationary phase is ground
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to a fine powder (to increase surface area) and particles are packed tightly together in a
steel column making it more difficult for the solvent to elute through the column. The
flow rate is increased by using high pressures to force the solvent through the column
(Schiel, Joseph, & Hage, 2010). Both increased surface area and high pressure allows for
a more efficient separation of compounds, hence the name high performance liquid
chromatography (Korecka & Shaw, 2009). HPLC is a highly precise technique capable
of separating out different compounds that possess even the slightest differences.
Therefore, HPLC may be used to identify the concentration of various compounds in
biological samples (e.g., concentration levels of DOX in cardiac tissue).
Several extensive reviews regarding the investigation of anthracyclines with the
use of HPLC have been published (Chen, Thoen, & Uckun, 2001; Loadman & Calabrese,
2001; Tjaden & de Bruijn, 1990). However; the analysis, isolation, and purification of
biomolecules can be accomplished by a number of different chromatographic modes
(DiFrancesco, Griggs, Donnelly, & DiCenzo, 2007; Dodde, et al., 2003; Kummerle, et
al., 2003; Li & Huang, 2004; Wall, McMahon, Crown, Clynes, & O'Connor, 2007). Each
method is based on interactions between the sample biomolecules and the packing
material of the column. The various methods of liquid chromatography are based on
separations due to the biomolecule’s charge, size, and hydrophobicity during elution
through porous packing material. Therefore, it is important to identify the inherent
differences between the modalities used for quantification purposes. The primary
methods used for quantification of biological samples, including methods specific to
DOX, will be reviewed in this section.
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Size Exclusion Chromatography
The most commonly used modes are size exclusion chromatography, ion
exchange chromatography, affinity chromatography, and adsorption chromatography.
Size exclusion chromatography (SEC) is a versatile chromatographic method in which
components of a biological sample are separated according to their molecular size with
respect to the porous packing material (Barth, Boyes, & Jackson, 1994; Yao & Lenhoff,
2004). Larger molecules elute from the column first due to their inability to penetrate the
pores of the packing material (Yao & Lenhoff, 2004), while some smaller molecules can
enter into the packing particles thus delaying their elution (Barth, et al., 1994; Stadalius,
Ghrist, & Snyder, 1987). SEC is an uncomplicated method for separating biomolecules,
because it is not necessary to keep the composition of the mobile phase constant during
elution (Barth, et al., 1994; Stulik, Pacakova, & Ticha, 2003). However, in comparison
to other methods such as reversed-phase chromatography, this method is limited by its
capacity for separation of biomolecules (Neue, 2008; Stulik, et al., 2003).
Affinity Chromatography
Affinity chromatography (AFC) is based on the properties of a molecule’s ability
to specifically bind to a ligand (Schiel & Hage, 2009). AFC is commonly used in basic
science research and pharmaceutical drug development for the purification of chemicals
or biomolecules using specific interactions between biological pairings (e.g., enzyme and
enzyme substrate) via ligand binding (Ohtsu, et al., 2005). Ligands are used in the
column packing material to adsorb specific biomolecules. Upon ligand binding, a
conformational change occurs and the elution of the biomolecule is altered. In
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comparison to other methods, AFC is an efficient and very selective technique used for
separation of large volumes of biomolecules (Neue, 2008; Schiel & Hage, 2009).
Ion Exchange Chromatography
The basis for ion exchange chromatography (IEC) is simple; charged
biomolecules will bind to oppositely charged molecules in column packing materials
(Jungbauer & Hahn, 2009). Proteins have charged molecules on their surfaces, which
change with the pH of the solution (Jungbauer & Hahn, 2009; Yigzaw, Hinckley, Hewig,
& Vedantham, 2009). Biomolecules with a greater charge bind more strongly to the
packing material regardless of pH, however, weaker charges are easily influenced by
slight changes in pH. IEC is a very selective separation technique and has a high binding
capacity that can be used on a wide variety of proteins over a short period of time
(Jungbauer & Hahn, 2009; Langford, Xu, Yao, Maloney, & Lenhoff, 2007) .
Reversed Phase Chromatography
Reversed phase liquid chromatography (RPLC) is a specific type of adsorption
chromatography that allows for separation based on hydrophobic interactions between the
biomolecule and the ligand on the chromatographic column (Roses, Subirats, & Bosch,
2009; Wang, Tian, Bi, & Row, 2009). Typically, the RPLC’s stationary phase contains a
large volume of hydrophobic ligands, while the mobile phase additives, such as acetic
acid, increase protein hydrophobicity by forming ion pairs that strongly adsorb to the
stationary phase (Nikitas & Pappa-Louisi, 2009; Wang, Tian, et al., 2009). The main use
for RPLC is for the separation peptides, however, less frequently, it can also be used to
separate proteins (Li & Huang, 2004; Neue, 2008; Wang, et al., 2008). The main draw to
RPLC is that the method is the most efficient of all the biopolymer separation techniques
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(Sandra, et al., 2008). RPLC is particularly effective for separating chemical compounds
in biological samples, which makes RPLC the most coveted mode for the determination
of anthracyclines, such as DOX, in plasma, serum, and tissues (Dodde, et al., 2003;
Kummerle, et al., 2003; Li & Huang, 2004; Urva, et al., 2009; Wall, et al., 2007).
High Performance Liquid Chromatography
and Doxorubicin
Several reverse phase methods for determination of anthracyclines in plasma,
serum, or tissues have recently been published (Ahmed, et al., 2009; Maudens, et al.,
2009; Salvatorelli, et al., 2009; Urva, et al., 2009). The most recent recommended
methods for anthracycline analysis are summarized in Table 2. Urva et al. (2009)
reported a less labor intensive method that was successfully used to quantify DOX
accumulation in plasma and cardiac samples following administration of an i.v. bolus
dose at 10 mg/kg in Swiss–Webster mice. A Zorbax 300SB C18 (250 mm × 4.6 mm,
5 µm) column was used for separation. The mobile phase was comprised of 25%
acetonitrile and 75% water in the presence of 0.1% triethylamine (pH 3). A constant
flow rate of 1.2 mL/min was used for the separation. Plasma and tissue sample treatment
involved a single protein precipitation step with perchloric acid. DOX and DAUN
retention times were reported to be 5.9 and 13.1 minutes, respectively. The limit of
detection for doxorubicin in the heart tissue was: 1.54 ng/mL. The method was validated
for precision and accuracy over a concentration range of 5-1000 ng/mL and DOX
accumulation was measured up to 3 days post DOX exposure. A significant decline in
DOX accumulation in measured parameters reduced quickly over a 12 hour period.
However, DOX was still detected in cardiac tissue 72 hours post treatment. The
aforementioned study’s methodology is most comparable to the method used in the study
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by Bradshaw et al. (2009) to quantify DOX in rat cardiac tissue. Bradshaw et al. (2009)
reported an HPLC method that successfully determined the accumulation of DOX in LV
tissue of sedentary and exercise trained rats. Similarly, other methods have reported the
use of HPLC in the determination of anthracyclines (Ahmed, et al., 2009; Arnold, Slack,
& Straubinger, 2004; DiFrancesco, et al., 2007; Gilbert, McGeary, Filippich, Norris, &
Charles, 2005; Kummerle, et al., 2003; Li & Huang, 2004; Urva, et al., 2009).
Specifically, DOX can be determined in various biological matrices (i.e. plasma, serum,
effluent, and tissues) using reverse phase HPLC (Kummerle, et al., 2003; Urva, et al.,
2009). EPI (Li & Huang, 2004), and doxorubicinol (DOX-ol) (Ahmed, et al., 2009;
Arnold, et al., 2004; DiFrancesco, et al., 2007; Gilbert, et al., 2005), a secondary alcohol
metabolite of DOX, were also quantified using various HPLC methods. Methods
specifics can vary based on the internal standards used for accumulation comparison,
sample preparation, column type, and detection. In the following section, various
methods’ specifics for the quantification of DOX will be reviewed.

(Urva, et al.,
2009)
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Doxorubicin

Doxorubicin, Doxorubicinol,
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Liquid–liquid
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Note: Abbreviations: HPLC- High performance liquid chromatography; C- Carbon; min- minutes.

(Bradshaw, et
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(Salvatorelli, et
al., 2009)

Doxorubicin

Mouse plasma,
kidney, liver,
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heart and brain

(Ahmed, et al.,
2009)

Doxorubicin
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Plasma
Saliva

(Maudens, et
al., 2009)
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Daunorubicin, Idarubicin,
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Zorbax
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Recommended methods for quantifying Doxorubicin accumulation.

Table 2

470 nm

477 nm

482 nm

480 nm

480 nm

Excitation

550 nm

560 nm

550 nm

560 nm

555 nm

Emission

28

28

29
Internal Standards
An internal standard is a known concentration of a known compound. It differs
from an analyte, in which the concentration of the compound is unknown. Typically, the
signal from an analyte is compared to the internal standard’s signal in order to calculate
the concentration of the analyte. DAUN is the most commonly used internal standard for
the quantification of DOX (DiFrancesco, et al., 2007; Kummerle, et al., 2003; Urva, et
al., 2009). However, with success, epidaunorubicin (EPIDAUN) was reportedly used as
an internal standard (Li & Huang, 2004). In a study by Bradshaw et al. (2009), DAUN
was used as an internal standard for the quantification of DOX accumulation in rat
cardiac tissue and eluted approximately 2 minutes after the elution of DOX.
Sample Preparation
In order for a biological sample to be analyzed using HPLC, it must first be
prepared for separation. With samples containing DOX, a purification step must be
completed. The most commonly used processes include deproteinization (Ahmed, et al.,
2009; Arnold, et al., 2004; Kummerle, et al., 2003; Urva, et al., 2009), liquid-liquid
extraction (Maudens, et al., 2009), solid phase extraction (DiFrancesco, et al., 2007; Li &
Huang, 2004), and back extraction (Loadman & Calabrese, 2001). Deproteinization (a
process of protein removal from a substance) occurs with the use of acids and it is an
essential step in the HPLC analysis of DOX. Acids used for deproteinization in previous
studies included perchloric acid, trichloroacetic acid and picric acid for protein
precipitation (Ahmed, et al., 2009; Bradshaw, et al., 2009; Kummerle, et al., 2003; Urva,
et al., 2009). Solid phase extraction (process by which compounds are dissolved or
suspended in a liquid) was successfully used to purify samples for the analysis of both
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DOX (DiFrancesco, et al., 2007) and EPI (Li & Huang, 2004). A very time intensive
technique was used by Gilbert et al. (2005) to purify plasma samples from parrots in
which deproteinization was followed by a liquid–liquid extraction and then a backextraction (a sequential extraction of organic material) for the analysis of DOX and
DOX-ol accumulation. Based on the reports from the studies mentioned afore, it may be
concluded that the purification of DOX, in biological samples, is not limited to technique.
Separation Column and Detection
The specificity of HPLC analyses depends largely on the separation column and
the detection method. For adequate separation and elution, the column must incorporate
the analyte molecule size. Many studies have used C-18 columns (18-carbon chain
packing material) (Arnold, et al., 2004; Bradshaw, et al., 2009; DiFrancesco, et al., 2007;
Kummerle, et al., 2003; Li & Huang, 2004; Urva, et al., 2009) and reported high accuracy
and precision when quantifying DOX, however, only two studies reported the use of a
less hydrophobic column, C-8 phenylhexyl (column containing a shorter carbon chain
packing material) (Ahmed, et al., 2009; Gilbert, et al., 2005) to quantify DOX. Results
from these studies suggest that DOX, due to its size, may be more easily eluted through a
C-18 column with greater separation than a C-8 column. Following the elution of DOX
through the column, it must be detected. Fluorescence (Bradshaw, et al., 2009; Gilbert, et
al., 2005; Kummerle, et al., 2003; Urva, et al., 2009), chemiluminescence (Ahmed, et al.,
2009), and tandem-mass spectrometry (Arnold, et al., 2004; DiFrancesco, et al., 2007; Li
& Huang, 2004) are the most commonly used methods in the detection of DOX in
biological samples. Thus, the detection of DOX is not limited to one type of detector;
however, some reports suggest that tandem-mass spectrometry may have a greater
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specificity over fluorescence detectors (Freisleben, Schieberle, & Rychlik, 2003; Sai,
Kaniwa, Ozawa, & Sawada, 2002).
Summary
DOX is an anthracycline antibiotic that has cytotoxic actions. The therapeutic use
of DOX to treat a wide array of cancers is limited by a dose-dependent cardiotoxicity.
DOX is known to have several adverse side-effects, however, acute and chronic
cardiotoxicity have received the most attention as both may eventually lead to heart
failure. It is well accepted that cardiotoxicity of DOX is associated with generation of
oxidative stress and an interference with mitochondrial function. While exercise has
been shown to be cardioprotective against DOX cardiotoxicity, a clear and consistent
mechanism to explain its cardioprotective effects is lacking. HPLC is a valuable
instrument that can be used to evaluate cardiac DOX accumulation. It was hypothesized
that exercise will reduce the accumulation of DOX in cardiac tissue, which may
contribute to the preservation of cardiac function and protect the heart against the acute
injury induced by DOX treatment. Therefore, it is possible that the cardioprotective
effect of chronic exercise preconditioning may be due to a reduction of DOX
accumulation in the cardiac tissue of rats receiving DOX treatment.
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CHAPTER III
METHODOLOGY
Experimental Design
The purpose of this study was to determine the effects of chronic exercise
preconditioning on DOX accumulation and cardiac function. This was achieved by
training rats using two different exercise protocols prior to DOX exposure (Figure 1).
DOX was administered 24 hours after the last training session as a bolus i.p. injection in
doses that are known to result in acute cardiac injury. The cumulative dose of DOX was
10 mg/kg. Control animals received a bolus i.p. injection of 0.9% saline. Rats were
sacrificed 1, 3, 5, 7, and 9 days post exposure and cardiac function was analyzed. One
day following sacrifice, DOX accumulation was analyzed via HPLC.
Subjects
Female Sprague-Dawley rats (10-11 week old, 190-210 g) were housed two per
cage in a temperature-controlled facility with a 12:12-hr light-dark cycle. Rats were
provided standard rat chow and water ad libitum. All protocols used for the study were
approved by the University of Northern Colorado Institutional Animal Care and Use
Committee (IACUC) and are in compliance with the Animal Welfare Act guidelines. All
rats were randomly assigned to sedentary (SED), treadmill (TM), or wheel running (WR)
exercise groups.
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Figure 1. Exercise Timeline and Experimental Design. Each open horizontal rectangle
( ) represents 1 week of involuntary treadmill running exercise. Each closed
horizontal rectangle (
) represents 1 week of voluntary wheel running exercise.
we
of treadmill
Open arrows (ò)) represent sacrifice times. SED = sedentary TM = 10 weeks
exercise; WR = 10 weeks of wheel running exercise; SAL = saline injection; DOX =
doxorubicin injection.
Exercise Training
Animals randomly assigned to TM ggroups participated in a progressive treadmill
training protocol for ten consecutive weeks. Animals assigned to participate in 10
consecutive weeks of TM exercise follow
followed a progressive training protocol that has
previously been shown to be cardioprotective against DOX
DOX-induced
induced cardiotoxicity
(Wonders, et al., 2009) (Table 3). Animals trained five days per week for 10 weeks
during their dark cycle. Rats initially ran at 13 m/min up a 5% grade for 20 minutes per
day. Exercise
cise intensity and duration gradually increased during weeks 1--4, until reaching
30 m/min and 18% grade for 60 minutes. This workload was maintained for the
remainder of thee study. When necessary, rats were motivated to run by manual prodding
and tapping on the equipment. Animals selected to participate
pate in voluntary wheel
running exercise were housed one per cage and had free access to commercially available
running wheels (MiniMitter, Bend, OR) 24 hours per day for 10 consecutive weeks.
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Wheel running distances were monitored using Vital View data acquisition systems
(MiniMitter, Bend, OR).
Table 3
Chronic exercise treadmill training protocol.
Variable
Speed (m/min)
Grade (%)
Duration (min)

1
13
5
20

2
21
10
30

3
26
15
30

4
30
18
60

Week
5
30
18
60

6
30
18
60

7
30
18
60

8
30
18
60

9
30
18
60

10
30
18
60

Drug Treatment
After the completion of the sedentary or activity period, all animals remained
sedentary 24 hours prior to treatment with DOX. Following the 24 hour sedentary
period, each animal was randomly assigned to one of four experimental groups as
illustrated in Figure 1: SED+SAL, SED+DOX, TM+DOX, WR+DOX. Animals
undergoing saline treatment received a 1.0 mL i.p. bolus injection of 0.9% saline.
Animals treated with DOX received a 10 mg/kg bolus injection of DOX (Bedford Labs,
Bedford, OH). Subgroups of rats from each primary group were sacrificed at 1, 3, 5, 7,
and 9 days following injections.
Cardiac Function
Left ventricle (LV) function was assessed in vivo and ex vivo. In vivo cardiac
function was assessed using transthoracic echocardiography on sedated rats with a
commercially available echocardiographic system (Toshiba Nemio 30; 10 MHz
transducer). Animals were sedated with ketamine (40 mg/kg, i.p.) and echocardiography
was completed within 10-15 minutes after the administration of the sedative. Animals
were placed in the left lateral decubitus position and the probe was positioned to obtain
short-axis, long-axis, and four-chamber views. From the short-axis view, an M-mode
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tracing of the LV was obtained for measures of septal wall thickness during systole
(SWs) and diastole (SWd), posterior wall thickness during systole (PWs) and diastole
(PWd), LV end systolic diameter (LVDs), and LV end diastolic diameter (LVDd).
Aortic flow was assessed from the five-chamber apical view using pulsed wave
Doppler, with the smallest possible sample volume placed at the level of the aortic
annulus. Using a four-chamber apical view, mitral flow was assessed using pulsed wave
Doppler with the smallest possible sample volume placed at the tips of the mitral valve.
LV mass was calculated as 1.04[(LVDd + PWd + SWd)3 – LVDd3], and fractional
shortening (FS) was calculated as (LVDd – LVDs)/LVDd.
From pulsed Doppler mitral and aortic flow images, the velocity time integral
(VTI), maximal flow velocity (Vmax), mean flow velocity (Vmean), acceleration time (AT),
and deceleration time (DT) were measured. Measures of filling time (FT) and ejection
time (ET) were obtained from mitral and aortic Doppler flow images, respectively. For
all measures, data from three consecutive cardiac cycles, when possible, was obtained
and averaged.
Ex vivo cardiac function was analyzed using an isolated working heart model
(ADInstruments, Colorado Springs, CO). This analysis was conducted immediately
following echocardiography procedures. After each animal received an i.p. injection of
heparinized (100U) sodium pentobarbital (50 mg/kg), the heart was quickly excised. The
aorta was cannulated and the heart was subjected to retrograde perfusion using Krebs
buffer (120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3,
17 mM glucose, and 0.5 mM EDTA) until the coronary vasculature was cleared of blood.
The pulmonary vein was cannulated and flow was re-directed to enter the left atrium.
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Preload was set at 10 cm H2O and afterload set at 100 cm H2O above the cannula. A
microtip catheter pressure transducer (Scisense, Ontario, Canada) was inserted into the
LV cavity via the apex for measurement of LVDP, maximal rate of pressure development
(dP/dtmax) and the maximal rate of pressure decline (dP/dtmin). Hearts were paced at 240
beats/min using electrodes attached to the cannulae, and LV performance data were
collected using a PowerLab/8e data acquisition system (ADInstruments, Colorado
Springs, CO) following a 5 minute equilibration period. LVDP was calculated by
subtracting left ventricular ESP from EDP.
Biochemical Analysis
High Performance Liquid
Chromatography
Left Ventricular Tissue Preparation. Immediately after the perfusion period,
hearts were trimmed free of surrounding connective tissue and fat, blotted dry, and
weighed. The LV was then isolated, flash frozen in liquid nitrogen, and stored at –80°C
for 24 hours. Tissue samples were then subjected to a drug extraction procedure taken
from previously validated methods (Alvarez-Cedron, Sayalero, & Lanao, 1999;
Bradshaw, et al., 2009). Approximately fifty milligrams of LV tissue was diluted with a
0.067 M phosphate buffer (pH 7.4) and homogenized at 8000 RPM for 20 seconds using
a Virtishear homogenizer (Virtis, Gardner, NJ). The concentration of heart tissue was
approximately 25 mg/mL. Homogenates were then subjected to protein precipitation by
adding 200 µL of a 50:50 (v/v) mixture of HPLC grade methanol and 40% ZnSO4 to 150
µL of homogenized heart tissue. Fifty microliters of DAUN (Sigma, St. Louis, MO) at an
initial concentration of 500 ng/mL was added to the sample as an internal standard. The
sample was vigorously vortexed for one minute before centrifugation at 1500g for 10
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minutes. The supernatant fluid was filtered through a 0.2 micron syringe filter and
injected directly onto the column to initiate the analytical method.
Analytical Method
The HPLC system consisted of two LC-10AT LC pumps for high-pressure
gradient elution (Shimadzu Co., Japan). A reverse-phase Zorbax Rx-C8 4.6mm x 15 cm
column (Agilent Technologies, Santa Clara, CA) was used for separation and operated at
40°C. The following mobile phase (solvent) line configuration was held for all analyzes:
solvent line A - HPLC-grade water, solvent line B - HPLC-grade acetonitrile, solvent line
C - phosphate buffer, and solvent line D - HPLC-grade methanol. At the end of each
day’s HPLC analyses, solvent line C was purged of phosphate buffer and stored in water
and solvent line B was purged of acetonitrile and stored in HPLC-grade methanol.
The initial phase conditioned the system in the following manner: 65:35 (v/v)
methanol/water at 0.1 mL/min flow rate through the column over-night and through the
next morning by the conditioning method displayed in Table 4. Figure 2 illustrates the
mobile phase composition profile used for the conditioning method.
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Table 4
HPLC mobile phase composition and pump parameters used for the system conditioning
program (conditioning method). The pump mobile phase program configuration was:
solvent line A - HPLC-grade water, solvent line B - HPLC-grade water, solvent line C HPLC-grade methanol, and solvent line D - HPLC-grade methanol. The initial mobile
phase composition was 65:35 (v/v) methanol (from solvent line D)/water (from solvent
line A) at a 0.1mL/min flow rate. Conc. = concentration of designated solvent.
Time
0.01
30.00
180.00
240.00
260.00
360.00
400.00

Mobile Phase Composition (%)

100

Module
Pumps
Pumps
Pumps
Pumps
Pumps
Pumps
Controller

Action
Total Pump A Flow
Solvent D Conc.
Solvent D Conc.
Solvent D Conc.
Solvent D Conc.
Solvent D Conc.
Stop

100

100

Value
1.00 mL/min
100.0%
100.0%
10.0%
10.0%
65.0%

90 90

90
80
70
65
60
65

65

35

35

50
40
35
30
20
10

0

10

0

10

0
0

50

100

150

200

250

300

350

400

Minutes

Figure 2. Mobile phase composition profile for the startup conditioning method (▲methanol, ■ - water). For this method, solvent lines B and C were held at 0% for the
duration of the run. The initial mobile phase composition was 65:35 (v/v)
methanol/water (from solvent line A). After the 400 minute run, the system returned to
the initial mobile phase composition.
The system was then stored in 65:35 (v/v) methanol/water until use. Before any
analysis, the system was conditioned by pumping 65:35 methanol/water, flowing at 0.1
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mL/min through the column overnight. To prepare the system for analyses, the analysis
setup method parameters were set as displayed in Table 5. Figure 3 illustrates the mobile
phase composition profile used for the setup method. Just prior to the end of the 60
minute run, the pumps were shut off, the setup method was stopped, and the run method
described in Table 6 was initiated. Therefore, the system was allowed to equilibrate for
at least 60 minutes with a mobile phase composition of (A) 0%, (B) 25%, (C) 75%, and
(D) 0% flowing at 1.0 mL/min before the analysis were performed. Before each use, the
mobile phase solvents (water, phosphate buffer, and methanol) were passed through a
MAGNA-R® nylon-supported plain 0.22 µm filter using a vacuum filtration apparatus
and were degassed by holding the filtered solvent under a vacuum for at least 20 minutes.
Acetonitrile was passed through a Teflon-laminated 0.22 µm filter using a vacuum
filtration apparatus and was degassed by holding the filtered solvent under vacuum for at
least 20 minutes.
Table 5
HPLC mobile phase composition and pump parameters used for the system analysis setup
program (setup method). The pump mobile phase configuration was: solvent line A HPLC-grade water, solvent line B - HPLC- acetonitrile, solvent line C - phosphate buffer,
and solvent line D - HPLC-grade methanol. The initial mobile phase composition was
65:35 (v/v) methanol (from solvent line D)/water (from solvent line A) at a 0.1mL/min
flow rate. Conc. = concentration of designated solvent.
Time
0.01
45.00
45.00
60.00

Module
Pumps
Pumps
Pumps
Controller

Action
Total Pump A Flow
Solvent C Conc.
Solvent B Conc.
Stop

Value
1.00 mL/min
75.0%
25.0%

40

Mobile Phase Composition (%)

100
90

75

75

25

25

0

0

80
70

65

60
50
40

35

30
20
10

0

0
0

10

20

30

40

50

60

Minutes

Figure 3. Mobile phase composition profile for the setup method (▲- methanol, ■ water, ♦ - phosphate buffer, ● - acetonitrile). For this method the initial mobile phase
composition was 65:35 (v/v) methanol (from solvent line D)/water (from solvent line A).
The final mobile phase composition was (A) 0%, (B) 25%, (C) 75%, and (D) 0% flowing
at 1.0 mL/min.
The system was prepared for sample analysis by initiating the run method given
in Table 6. Figure 4 illustrates the mobile phase composition profile used for the run
method. The following mobile phase solvent configuration was held for the analyses:
solvent line A - HPLC-grade water, solvent line B - HPLC-grade acetonitrile, solvent line
C - phosphate buffer, and solvent line D - HPLC-grade methanol. The system initial
composition of (A) 0%, (B) 25%, (C) 75%, and (D) 0% flowing at 1.0 mL/min was held
for four minutes, a linear gradient was then used to change the mobile phase to
phosphate:acetonitrile (50:50) over the next four minutes (8 minute mark).
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Table 6
HPLC mobile phase composition and pump parameters used for the system analysis (run
method). The pump mobile phase configuration was: solvent line A - HPLC-grade
water, solvent line B - HPLC- acetonitrile, solvent line C - phosphate buffer, and solvent
line D - HPLC-grade methanol. The initial solvent composition was (A) 0%, (B) 25%,
(C) 75%, and (D) 0% flowing at 1.0 mL/min. Conc. = concentration of designated
solvent.
Time
0.01
4.00
4.00
14.00
14.00
16.00
16.00
18.00
18.00
20.00

Module
Pumps
Pumps
Pumps
Pumps
Pumps
Pumps
Pumps
Pumps
Pumps
Controller

Action
Total Pump A Flow
Solvent C Conc.
Solvent B Conc.
Solvent C Conc.
Solvent B Conc.
Solvent C Conc.
Solvent B Conc.
Solvent C Conc.
Solvent B Conc.
Stop

Value
1.00 mL/min
75.0%
25.0%
50.0%
50.0%
5.0%
95.0%
75.0%
25.0%

Mobile Phase Composition (%)

100
90

75
75

80

95

95

75

5

5

25

16

18

20

70
60
50
40

50

50

30
20

25

25

10
0
0

2

4

6

8

10

12

14

Minutes

Figure 4. Mobile phase composition profile used for the run method (♦ - phosphate
buffer, ● - acetonitrile). For this method the initial mobile phase composition was (A)
0%, (B) 25%, (C) 75%, and (D) 0% flowing at 1.0 mL/min.
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The secondary mobile phase was maintained ten minutes into the run (14 minute
mark), at which time a linear gradient was used to change the mobile phase of
phosphate:acetonitrile from (50:50) to (5:95) over the course of the next two minutes (16
minute mark). This phase was maintained for two minutes (18 minute mark) and then the
mobile phase returned via a linear gradient to the initial conditions
(phosphate:acetonitrile (75:25), 20 minute mark). The photo diode-array detector
absorbance wavelength range was set to 328-342 nm, all other settings were set to
program defaults. The fluorescence detector SPD-10Avp UV (Shimadzu Co., Japan)
used for excitation/emission wavelengths was maintained at 470/550 nm, the gain was
raised to 16X, and all other settings were set to program defaults. The detector lamps
were turned on a minimum of one hour prior to analysis to allow for proper stabilization.
Data analysis was performed using Shimadzu CLASS-VP 5.0 data analysis software
(Shimadzu Co., Japan). Quantification of DOX in LV samples was determined from the

Ratio of Instrument
Response in Area Under
Curve (Dox/Daun)

peak area of each component relative to calibration standard curve displayed in Figure 5.

3
2.5
2
1.5
1
0.5
0
0

10

20

30

40

50

60

70

80

Dox Concentration (ng/ml)
Figure 5. Doxorubicin standard curve with daunorubicin. The y-intercept equals 0.309x
+ 0.344 and the R2 = 0.9974.
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Preparations of Solutions
HPLC mobile phase stock phosphate buffer (100 mM (0.1 M) NaH2PO4). To
make a total volume of 0.5 L, 6.9 g of solid sodium phosphate monobasic (NaH2PO4) was
dissolved in approximately 400 mL of HPLC-grade water. The solution was then placed
in a 500 mL volumetric flask and diluted to volume with HPLC-grade water. The buffer
solution was passed through a 0.22 nylon filter and stored in an amber bottle at 4 °C.
Running phosphate buffer (10 mM (0.01 M) NaH2PO4). To make a total volume
of 1.0 L, 100.0 mL of stock phosphate buffer (0.1 M NaH2PO4) was diluted in
approximately 600 mL of HPLC-grade water and the pH was adjusted to 3.0 using 0.01
M phosphoric acid (0.01 M phosphoric acid was made by adding 0.17 mL of 14.7 M
phosphoric acid to 250.0 mL of HPLC grade water). The solution was then placed in a
1.0 L volumetric flask and diluted to volume with HPLC-grade water. The buffer
solution was passed through a 0.22 nylon filter and stored in a clear bottle at 4 °C.
LV tissue-preparation phosphate buffer (0.067 M NaH2PO4 at pH 7.4). To make
a total volume of 0.2 L, 134.0 mL of stock phosphate buffer (0.1 M NaH2PO4) was
diluted in approximately 150 mL of HPLC-grade water and the pH will be adjusted to 7.4
using 5 M NaOH. The solution was then placed in a 200 mL volumetric flask and diluted
to volume with HPLC-grade water. The buffer solution was passed through a 0.22 nylon
filter and stored in a clear bottle at 4 °C.
Statistical Analysis
Group data are reported as mean (M) ± standard error of mean (SEM). To
determine significant differences in ex vivo and in vivo cardiac function, a three-way
(drug X exercise X time) multiple analysis of variance (MANOVA) was used. The
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dependent variables of in vivo function are M-VTI, M-Vmax, M-Vmean, A-VTI, A-Vmax, AVmean, and FS. The ESP, EDP, LVDP, dP/dtmax, and dP/dtmin were used as dependent
variables of ex vivo function. To determine significant differences in DOX accumulation,
a two-way (exercise X time) analysis of variance (ANOVA) was used. Individual means
of all DOX groups were then compared to the SED+SAL control mean using independent
sample t-tests. A significant level of p < 0.05 was used for all statistical analyses.
Statistical Analysis System (SAS; SAS Institute Inc., Cary, North Carolina) software was
used to analyze all data.
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CHAPTER IV
RESULTS
Introduction
The purpose of this study was to determine the effects of exercise preconditioning
on cardiac DOX accumulation and to what extent it is related to DOX-mediated cardiac
dysfunction. In addition, an HPLC based method was used for a time-course
determination of DOX clearance in rat left ventricular tissue.
General Observations
Nineteen animals died during the experiment (SED+DOX, n = 6; TM+DOX, n =
7; WR+DOX, n = 7). Therefore, the mortality rate in the SED+DOX group was
approximately 9% (6 of 67) and the mortality rate was approximately 11% in both the
TM+DOX and WR+DOX groups (7 of 65). Running distances for WR+DOX groups
were recorded weekly (Figure 6) and peaked at 49718 ± 17925 m during week 5. Using
the previously described HPLC method, mean DOX retention time for all samples was
6.47 minutes and mean DAUN retention time was 8.78 minutes. Typical chromatograms
of sedentary and exercise groups 1 day post DOX exposure are shown in Figure 7.
Figure 8 displays typical chromatograms of sedentary and exercise groups 7 days
following DOX exposure.

Mean Weekly Running Distance (meters)
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Figure 6. Weekly running distance for WR+DOX groups
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Figure 7. Chromatogram of SED+DOX 1 day post (A) and TM+DOX 1 day post (B)
DOX exposure analyzed by the proposed HPLC method

A
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DOX

Figure 8. Chromatogram of SED+DOX 7 day (A) and WR+DOX 7 day (B) post DOX
exposure analyzed by the proposed HPLC method
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Cardiac Function
In Vivo Cardiac Function
The selected in vivo variables M-VTI, M-Vmax, M-Vmean, A-VTI, A-Vmax, A-Vmean
and FS are displayed in Figures 9-15. The main effect of DOX treatment on in vivo
cardiac function was significantly different across all groups, F (9, 110) = 2.81, p =
0.0052. A post hoc test was used to determine which group’s in vivo function was
different. A significant difference for in vivo function was observed between SED+SAL
and SED+DOX, F (9, 110) = 2.81, p < 0.0052. Likewise, a significant difference for in
vivo function was observed between SED+SAL and TM+DOX, F (9, 110) = 13.03, p <
0.0001 and between SED+SAL and WR+DOX, F (9, 110) = 9.09, p < 0.0001.
For in vivo cardiac function there was a significant exercise effect, F (18, 220) =
6.46, p = 0.0001. However, post hoc testing revealed no significant differences existed
between SED+DOX and TM+DOX, SED+DOX and WR+DOX, or TM+DOX and
WR+DOX, p > 0.05. Additionally, a significant effect of time following DOX treatment
on in vivo cardiac function was observed for all groups F (9, 110) = 3.14, p = 0.0021.
Doppler blood flow measurements were obtained from the mitral valve to assess
the LV diastolic functional changes for all experimental groups and individual t-tests for
in vivo variables were performed for comparisons to SED+SAL. DOX treatment
significantly impaired M-VTI in SED+DOX groups at 3, 5, 7 and 9 days when compared
to SED+SAL (Figure 9, p < 0.05). However, the impairment was less obvious in
TM+DOX and WR+DOX groups. When compared to SED+SAL, M-VTI was only
reduced 5 days post DOX treatment in WR+DOX while TM+DOX groups were impaired
at 7 and 9 days post exposure. Similar to M-VTI, mitral maximal and mean blood flow

49
velocities were significantly reduced in the SED+DOX groups when compared to
SED+SAL (Figures 10-11, p < 0.05); however, M-Vmax and M-Vmean in TM+DOX and
WR+DOX groups were not statistically different from the SED+SAL group at any time
point (p > 0.05).
Doppler measurements obtained at the aortic valve revealed that DOX treatment
significantly impaired A-VTI in SED+DOX groups at 3 and 7 days when compared to
SED+SAL (Figure 12, p < 0.05). With the exception of TM+DOX 1 day post DOX
treatment, A-VTI in TM+DOX and WR+DOX groups was not significantly reduced
when compared to SED+SAL (p > 0.05). Aortic blood flow velocities (A-Vmax and AVmean) were significantly reduced in the SED+DOX group when compared to SED+SAL
(Figures 13-14, p < 0.05). However, TM+DOX and WR+DOX groups were not
statistically different from the SED+SAL group at any time (p > 0.05). In addition to
impaired Doppler measurements, DOX significantly impaired FS in the sedentary groups.
A significant reduction in FS was observed in SED+DOX at all time points when
compared to SED+SAL (Figure 15, p < 0.05), while FS was not significantly different
than SED+SAL at any time point for TM+DOX or WR+DOX.
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Figure 10. In vivo mitral maximal flow velocity
* significant difference from SED+SAL

TM+DOX

WR+DOX

51

M-Vmean (cm/s)

75

*
50

1
3
5
7
9

*
*

*

*

25

0
SED+SAL

SED+DOX

TM+DOX

WR+DOX

Figure 11. In vivo mitral mean flow velocity
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Figure 13. In vivo aortic maximal flow velocity
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Figure 14. In vivo aortic mean flow velocity
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Ex Vivo Cardiac Function
Following echocardiographic measurements, LV function was analyzed using an
isolated working heart apparatus. This model allows for ex vivo LV function analysis
without intrinsic influence from the nervous and endocrine systems. The selected ex vivo
variables ESP, EDP, LVDP, dP/dtmax and dP/dtmin are displayed in Figures 16-20
(unpaced) and Figures 21-25 (paced). The main effect of DOX treatment on ex vivo
cardiac function was significantly different across all groups, F (30, 479.11) = 2.68, p <
0.0001. A post hoc test was used to determine which group’s ex vivo function was
different. A significant difference for ex vivo function was observed between SED+SAL
and SED+DOX, F (10, 163) = 2.17, p = 0.0222. Additionally, a significant difference for
ex vivo function was observed between SED+SAL and TM+DOX, F (10, 163) = 4.77, p
< 0.0001 and between SED+SAL and WR+DOX, F (10, 163) = 3.35, p = 0.0005.
For ex vivo cardiac function there was a significant exercise effect, F (20, 326) =
3.06, p < 0.0001. Post hoc testing revealed a significant difference existed between
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SED+DOX and TM+DOX groups, F (10, 163) = 2.23, p = 0.0186. However, no
significant differences were observed between SED+DOX and WR+DOX groups, F (10,
163) = 1.66, p = 0.0944; or TM+DOX and WR+DOX groups, F (10, 163) = 1.25, p =
0.2625. Additionally, a significant effect of time following DOX treatment on ex vivo
cardiac function was observed for all groups F (10, 163) = 11.45, p < 0.0001.
Unpaced Data
Unpaced pressure measurements were obtained to assess the LV functional
changes for all experimental groups and individual t-tests for ex vivo variables were
performed for comparisons to SED+SAL. DOX treatment alone significantly impaired
ESP in SED+DOX groups at 5, 7 and 9 days when compared to SED+SAL (Figure 16, p
< 0.05). However, the decrement was less pronounced in TM+DOX and WR+DOX
groups. When compared to SED+SAL, ESP was significantly higher 1 day post DOX
treatment (p < 0.05). The reduction at days 7 and 9 in TM+DOX and day 9 in the
WR+DOX was significant when compared to SED+SAL (Figure 16, p < 0.05).
Interestingly, EDP was not significantly different between SED+SAL and SED+DOX
(Figure 17, p > 0.05). However, when compared to SED+SAL, EDP was significantly
lower at day 1 in TM+DOX and significantly higher at day 3, while WR+DOX was
significantly higher 1 day post DOX treatment.
Similar to ESP, DOX treatment alone significantly impaired LVDP in SED+DOX
groups at 5, 7 and 9 days when compared to SED+SAL (Figure 18, p < 0.05). However,
the decrement was less pronounced in TM+DOX and WR+DOX groups. When
compared to SED+SAL, LVDP was significantly higher 1 day post DOX treatment (p <
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0.05). The reduction at 7 and 9 days in the TM+DOX groups and day 9 in the WR+DOX
was significant when compared to SED+SAL (Figure 18, p < 0.05).
In SED+DOX groups, at 5 and 9 days, a significant impairment of dP/dtmax and
dP/dtmin was observed when compared to SED+SAL (Figure 19 and Figure 20,
respectively, p < 0.05). However, dP/dtmax in TM+DOX at day 1 was significantly
greater than SED+SAL (p < 0.05). The WR+DOX groups at 5 and 9 days displayed a
significant impairment of dP/dtmax when compared to SED+SAL (Figure 19, p < 0.05),
while the impairment was not evident in TM+DOX until 9 days post DOX treatment. At
the 1 day time point, TM+DOX and WR+DOX displayed improved dP/dtmin when
compared to the SED+SAL group (Figure 20, p < 0.05). When compared to SED+SAL,
impairment was evident at the 7 day time point in TM+DOX and day 9 in TM+DOX and
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WR+DOX (Figure 20, p < 0.05).
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Figure 17. Unpaced ex vivo end diastolic pressure
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Figure 18. Unpaced ex vivo left ventricular pressure development
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Figure 19. Unpaced ex vivo maximal rate of pressure development
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Paced 240 Data
To obtain standardized LV pressure measurements, hearts were paced at 240
beats/min following the collection of unpaced data. DOX treatment alone significantly
impaired ESP in SED+DOX groups at all the measured time points when compared to
SED+SAL (Figure 21, p < 0.05). However, the decrement did not occur in TM+DOX
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until days 7 and 9. In contrast to TM+DOX, WR+DOX displayed significant impairment
when compared to SED+SAL at 3, 5, 7, and 9 days (Figure 21, p < 0.05). Comparable to
unpaced EDP, paced EDP was not significantly different between SED+SAL and
SED+DOX (Figure 22, p > 0.05). However, when compared to SED+SAL, EDP was
significantly lower at day 1 in TM+DOX and significantly higher at day 3, while
WR+DOX was significantly higher 1 day post DOX treatment.
Similar to ESP, DOX treatment alone significantly impaired LVDP in SED+DOX
groups at 1, 3, 5, 7 and 9 days (Figure 23, p < 0.05 vs. SED+SAL). When compared to
SED+SAL, LVDP was significantly lower 3, 7, and 9 day post DOX treatment in
TM+DOX and at 3, 5, and 9 days post exposure in WR+DOX (p < 0.05). At 3, 5, 7 and 9
days, SED+DOX, displayed a significant impairment of dP/dtmax when compared to
SED+SAL (Figure 24, p < 0.05). However, TM+DOX displayed significant differences
in dP/dtmax at 3, 7 and 9 days (p < 0.05 vs. SED+SAL). Significant impairment of
dP/dtmax in WR+DOX was observed at 3, 5 and 9 days (p < 0.05 vs. SED+SAL).
Impairment of dP/dtmin occurred in SED+DOX at 5, 7 and 9 days (Figure 25, p < 0.05 vs.
SED+SAL). However, dP/dtmin impairment in TM+DOX and WR+DOX occurred at 3
and 9 days post DOX treatment (Figure 25, p < 0.05 vs. SED+SAL).
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Figure 23. Paced (240) ex vivo left ventricular pressure development
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Figure 25. Paced (240) ex vivo maximum rate of pressure decline
* significant difference from SED+SAL

Biochemical Analysis
Doxorubicin Accumulation
After all functional analyses were performed, LV samples were isolated and flash
frozen in liquid nitrogen. Twenty-four hours following sacrifice, cardiac DOX
accumulation was analyzed using HPLC. All data are presented in Figure 26. DOX
accumulation was significantly different between groups, F (2,145) = 40.38, p < 0.001.
A post hoc test was used to determine which group’s DOX accumulation was different.
The greatest accumulation of DOX was observed in SED+DOX 1 day post injection.
When compared to SED+DOX (day 1), DOX accumulation in TM+DOX (day 1) and
WR+DOX (day 1) groups was significantly reduced (Figure 26, p < 0.05).
Similarly, DOX accumulation in SED+DOX at both 3 and 5 days was
significantly greater than both TM+DOX and WR+DOX at 3 and 5 days, respectively (p
<0.05). DOX accumulation in TM+DOX and WR+DOX groups was non-existent at both
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7 and 9 days. Because DOX accumulation remained elevated in SED+DOX at 7 days, it
was significantly greater than TM+DOX and WR+DOX groups (p < 0.05). Unlike the
exercised groups DOX was not completely cleared from the LV until 9 days after
treatment. DOX accumulation was not significantly different between TM+DOX and

DOX Accumulation (ng DOX/g LV)

WR+DOX at any time point (p > 0.05).
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Figure 26. Accumulation of DOX in rat LV tissue.
* Significant difference from SED+DOX
Summary
Using the described HPLC based method, DOX accumulation was successfully
quantified in the LV of female rats. In this study, DOX-induced chronic cardiotoxicity
resulted in both in vivo and ex vivo cardiac dysfunction. However, 10 weeks of either
involuntary or voluntary exercise preconditioning preserved cardiac function. Significant
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differences were observed between sedentary and exercise groups for DOX
accumulation, suggesting that reduced DOX accumulation may be one of the underlying
mechanisms responsible for the cardioprotective effects of exercise.
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CHAPTER V
DISSCUSSION
Introduction
The purpose of this study was to determine if exercise preconditioning reduces
cardiac DOX accumulation, thereby providing a possible mechanism to explain the
cardioprotective effects of exercise against DOX cardiotoxicity. The results indicate that
exercise had a profound effect on DOX accumulation as evidenced by significant
decreases in LV DOX accumulation 1, 3, 5, and 7 days after injection. Additionally,
DOX treatment resulted in significant cardiac function impairment at 1, 3, 5, 7, and 9 day
time points when compared to SED+SAL. Ten weeks of exercise preconditioning prior
to DOX treatment attenuated these responses, suggesting that exercise-mediated
cardioprotection is afforded by decreases in cardiac DOX accumulation.
Time-course of Doxorubicin Cardiotoxicity
DOX is a highly effective antineoplastic agent and used to treat a variety of
cancers including breast, bladder, Hodgkin’s and non-Hodgkin’s lymphomas. However,
its use clinically is limited by a dose-dependent cardiotoxicity that can subsequently lead
to heart failure (Lipshultz, et al., 2005; Singal, et al., 2000). The acute form of
cardiotoxicity often develops within hours or days following DOX treatment (Ferrans, et
al., 1997; Tokarska-Schlattner, et al., 2006). Patients receiving DOX may display signs
of acute cardiotoxicity including EKG changes, hypotension, myocarditis and pericarditis
(Schimmel, et al., 2004). In experiments using a rat model, indices of DOX-mediated
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cardiotoxicity are commonly reported as impairments to in vivo and ex vivo cardiac
function variables (Hydock, Lien, & Hayward, 2009; Hydock, et al., 2008; Hydock, et al.,
2010). This investigation examined the effects of DOX on in vivo and ex vivo cardiac
function over time. The selected variables measured in the current investigation are
indicative of systolic (FS, A-Vmax, A-Vmean, ESP, LVDP and dP/dtmax) and diastolic
(M-Vmax, M-Vmean, EDP and dP/dtmin) cardiac function. Cardiac dysfunction induced
by DOX treatment resulted in reduced Doppler blood flow measurements, decreased FS,
ESP, LVDP, and dP/dtmax, and increased dP/dtmin at 1, 3, 5, 7 and 9 days post treatment
with a greater tendency of impaired function as time progressed.
Cardiac dysfunction has been reported to occur 10 days (Hydock, et al., 2008), 7
days (Hayward & Hydock, 2007), 5 days (Chicco, Hydock, et al., 2006; Chicco,
Schneider, et al., 2006; Hydock, Lien, & Hayward, 2009; Wonders, et al., 2008), and
even 1 day (Neilan, et al., 2006) post DOX treatment with cumulative doses varying from
10-20 mg/kg. However, a cumulative dose of 9 mg/kg (Monti, Prosperi, Supino, &
Bottiroli, 1995) has been shown to decrease LVDP 10 days following DOX exposure and
7.5 mg/kg (Sacco, et al., 2003) was responsible for a decline in dP/dtmax 3 days post DOX
treatment. It is understood that both the cumulative dose and time course of DOX
treatment play an important role in the onset and degree of cardiac dysfunction (Minotti,
Menna, et al., 2004). Hayward and Hydock (2007) assessed the effects of different DOX
dosing schedules on in vivo cardiac function in male rats. The time course of cardiac
dysfunction was clearly affected by the DOX treatment regimen. In the current study,
female rats received the same DOX regimen (10 mg/kg bolus i.p. injection of DOX)
which resulted in a similar reduction in FS (-24%) 7 days post DOX treatment when
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compared to the previously reported reduction of FS (-22%) in male rats (Hayward &
Hydock, 2007). Furthermore, previous studies have reported comparable declines in
Doppler blood flow measurements in rats receiving a 10-15 mg/kg cumulative dose of
DOX evidenced by a significant decrease in M-Vmax and M-Vmean (Hydock, et al., 2010),
A-TVI (Hayward & Hydock, 2007), A-Vmax and A-Vmean (Hayward & Hydock, 2007;
Hydock, Lien, & Hayward, 2009).
In this investigation, 10 mg/kg of DOX significantly impaired not only in vivo
cardiac function but also ex vivo cardiac function in female rats 3, 5, 7 and 9 days after
treatment. Similarly, in vivo and ex vivo measurements of cardiac function in rats
receiving a 10 mg/kg bolus of DOX, showed that at 5 and 10 days post treatment, there
were significant decreases in Doppler measurements, dP/dtmax and LVDP (Hydock, et al.,
2008). The SED+DOX group displayed classic signs of DOX cardiotoxicity including
reductions in ESP, LVDP, dP/dtmax and impaired dP/dtmin. These general observations
corroborate with findings reported in several other studies of DOX-mediated
cardiotoxicity (Chicco, Hydock, et al., 2006; Chicco, et al., 2005; Chicco, Schneider, et
al., 2006; Hydock, Lien, Jensen, Schneider, & Hayward, 2011; Hydock, et al., 2008;
Hydock, et al., 2010; Wonders, et al., 2009; Wonders, et al., 2008). Numerous
mechanisms are likely to contribute to the dysfunction observed with DOX treatment in
the sedentary rats. Previous studies suggest DOX treatment results in the formation of
RONS (Sarvazyan, 1996), apoptosis (Kumar, Kirshenbaum, Li, Danelisen, & Singal,
1999), mitochondrial dysfunction (Oliveira, Santos, & Wallace, 2006) and impaired Ca2+
handling in the cardiomyocyte (Hirano, Agata, Iguchi, & Tone, 1995; Kim, et al., 2006).
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Collectively, these mechanisms are thought to have the greatest contribution to DOXmediated cardiotoxicity.
Effects of Exercise on Doxorubicin
Cardiotoxicity
In the present study, a 10 mg/kg bolus dose of DOX resulted in significant in vivo
and ex vivo cardiac dysfunction in sedentary animals 1, 3, 5, 7 and 9 days post DOX
treatment. This dysfunction was associated with DOX accumulation in cardiomyocytes.
Conversely, rats that participated in either voluntary wheel running or treadmill exercise
for 10 weeks did not exhibit the same degree of cardiac dysfunction. Furthermore, they
displayed significantly less DOX accumulation at 1, 3, 5 and 7 days following DOX
administration. Previous studies have determined that exercise preconditioning can
attenuate DOX-induced cardiotoxicity (Chicco, Schneider, et al., 2006; Hydock, et al.,
2011; Hydock, et al., 2008; Hydock, et al., 2010; Wonders, et al., 2009). As expected,
general observations from the current investigation coincide with previous studies that
used exercise preconditioning to mitigate the cardiotoxic effects of DOX.
A novel investigation conducted by Chicco et al., (2005) was the first to provide
evidence supporting chronic voluntary exercise prior to DOX exposure in the attenuation
of cardiac dysfunction. Until that time, experiments had shown promise for exerciseinduced cardioprotection against DOX cardiotoxicity; however, cardiac function was not
addressed (Ascensao, Magalhaes, et al., 2005b; Combs, Hudman, & Bonner, 1979; Ji &
Mitchell, 1994). A follow up study was conducted by Chicco et al., (2006) in which rats
trained on a treadmill for 12 weeks. Five days following a 15 mg/kg bolus i.p. injection
of DOX, cardiac function was assessed. Results indicated that LVDP, dP/dtmax, and
dP/dtmin were significantly impaired in sedentary DOX treated rats compared to exercise
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trained rats. Collectively, results from these studies suggest that cardioprotection from
DOX-induced dysfunction is achieved regardless of exercise modality. Therefore, results
from the current investigation were as expected and voluntary wheel running afforded
similar cardioprotection as treadmill exercise. Additionally, it was hypothesized that
both treadmill and wheel running exercise prior to DOX treatment would result in less
DOX accumulation when compared to sedentary rats. Thus, exercise preconditioning
would not only improve cardiac function but also offer cardiomyocytes direct protection
from DOX cardiotoxicity by reducing the degree of DOX exposure.
The use of voluntary exercise as a training regimen has been shown to increase
the sarcomere length-tension relationship, cardiac contractility (Lambert & Noakes,
1990; Natali, Turner, Harrison, & White, 2001; Natali, et al., 2002) and oxygen
consumption (Lambert & Noakes, 1990; Yano, Yano, Kinoshita, & Tsuji, 1997). Similar
findings have been reported with treadmill exercise, evidenced by increased
cardiomyocyte contractility and oxygen consumption (Wisloff, Helgerud, Kemi, &
Ellingsen, 2001; Wisloff, Loennechen, et al., 2001). Furthermore, the cardiovascular
adjustments between the two modalities appear to be similar (Yancey & Overton, 1993).
In the current study, both preconditioning modalities resulted in cardioprotection from
DOX-mediated dysfunction and less DOX accumulation compared to SED+DOX.
Additionally, DOX accumulation was not affected by modality evidenced by similar
observations of LV DOX in TM+DOX and WR+DOX groups. Thus, exercise
preconditioning, independent of modality, protected against cardiotoxicity as a result of
reduced DOX accumulation.
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It has previously been suggested that subtle differences in exercise-mediated
stress exist between voluntary and involuntary exercise (Moraska, Deak, Spencer, Roth,
& Fleshner, 2000; Moraska & Fleshner, 2001). Moraska et al., (2001) reported that
voluntary wheel running can reduce the deleterious effect of stress on immune function
and involuntary treadmill training (Moraska, et al., 2000) elevated lymphocyte nitrite
concentrations and suppressed lymphocyte proliferation, common immune responses, as
the result of chronic stress. Thus, the exercise intensity from the aforementioned
modalities may result in different chronic stress.
In the current study, exercise preconditioning prevented the in vivo and ex vivo
cardiac dysfunction observed with DOX treatment alone. Several mechanisms may be
responsible for the observed cardioprotective effects of exercise preconditioning. Most
noteworthy, evidence that cardiac DOX accumulation was significantly lower in
TM+DOX and WR+DOX hearts at 1, 3, 5, and 7 day time points suggest that a reduction
in cardiac DOX exposure may be responsible for the preservation in cardiac function.
Mechanisms of Cardioprotection
This study demonstrated, for the first time, that exercise mitigated DOX
accumulation and afforded cardioprotection. Determining the underlying mechanism
behind exercise-induced cardioprotection from DOX has been of great interest. The
observed reduction in LV DOX accumulation, as the result of exercise preconditioning,
offers the greatest contribution to the explanation of exercise-mediated cardioprotection
against DOX-induced cardiotoxicity. While these results confirm an exercise effect on
DOX accumulation in the heart, the exact mechanisms responsible for the exercisemediated reduction of LV DOX are still unknown. Therefore, the following discussion
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will focus on the theoretical foundation for an exercise-induced reduction in DOX
accumulation in cardiomyocytes.
Doxorubicin Accumulation
One potential explanation for less DOX accumulation in exercise preconditioned
rats may be due to increased DOX extrusion as the result of an upregulation of ABC
transporters. It is commonly accepted that cancer cells have the ability to develop a drug
resistance phenotype (Shen, et al., 2008; Sorokin, 2004). Several mechanisms are
thought to contribute to the drug resistance phenotype including increased drug extrusion,
decreased permeability, altered drug metabolism and deactivation (Davin-Regli, et al.,
2008). Additionally, non-cancerous cells, such as cardiomyocytes, display drug resistant
mechanisms as a means for inherent cytoprotection (Jungsuwadee, et al., 2009). For
example, cardiomyocytes normally express ABC transporters to allow or deny access of
nutrients and xenobiotics. Recently, numerous reports involving experimental
enhancement of ABC transporters have been shown to effectively pump xenobiotics out
of the cell (Dazert, et al., 2003; Dong, et al., 2009; Gradilone, et al., 2008; Krause, et al.,
2007; Meissner, et al., 2007; Shen, et al., 2008; Zhang, et al., 2009). The subfamily
proteins that are most involved in the transport of xenobiotics, including DOX, are
multidrug resistance proteins (MDR), MRPs and ABCA. Specific to location and tissue
type, MDR and MRPs are sub-categorized (i.e. MDR-1, MRP-1, MRP-2, MRP-3, MRP4, MRP-5, and ABCA-1).
Sub-family ABC transporters including a p-glycoprotein MDR-1 (Beaulieu,
Demeule, Ghitescu, & Beliveau, 1997; Meissner, et al., 2004), MRP-1, MRP-2 (Rosati, et
al., 2003), MRP-5 (Dazert, et al., 2003; Meissner, et al., 2007) and ABCA-1 (Nishimura,
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Naito, & Yokoi, 2004) expression occurs in cardiac tissue. The aforementioned protein
transporters may offer some insight to the transport of DOX and the regulation of its
anticipated toxicities. Bellamy et al, (1995) reported cardiac DOX accumulation
increased two-fold in non-tumor bearing mice when treated with a combination of DOX
and Cyclosporin A, a potent MDR-1 inhibitor. In addition, a greater degree of
myocardial insult was observed in mice exposed to the combination of DOX and
Cyclosporin A than in those mice not receiving the combined treatment. A similar
finding was reported in MDR-1 knock-out mice (mdr1a-/-) 24 hours post DOX treatment.
The accumulation of DOX and DOX-ol were greater than two-fold higher in the hearts of
(mdr1a-/-) mice when compared to control mice (van Asperen, van Tellingen, Tijssen,
Schinkel, & Beijnen, 1999). In vitro inhibition of ABCA-1 genes via extracellular signalregulated kinases (ERK) resulted in increased DOX accumulation determined by
fluorescence microscopy (Shukla, et al.). Furthermore, isolated cardiomyocytes from
Sprague-Dawley rats that were treated with calcium channel blockers in vitro to reverse
the multidrug resistant phenotype showed an increased concentration of DOX and
cardiotoxicity as indicated by increased heart levels of lactate dehydrogenase (Santostasi,
Kutty, & Krishna, 1991). Similarly, it has been demonstrated that an enhancement of
expression and/or activity of ABC transporters in the heart results in a desirable drug
resistance phenotype (Dell'Acqua, Polishchuck, Fallon, & Gordon, 1999; Granzotto, et
al., 2004; Magnarin, et al., 2004). Dell'Acqua et al., (1999) reported transgenic mice that
overexpressed the MDR-1 gene displayed greater cardioprotection from a 30 mg/kg
cumulative dose of DOX when compared to control mice. Collectively, these studies
have demonstrated that a blockade or enhancement of ABC transporters significantly
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influences extrusion of DOX and/or DOX-ol, and the subsequent drug exposure is related
to heart damage. This notion confirms the important role of ABC transporters in
cardioprotection from DOX-mediated cardiotoxicity.
Previous work suggests that exercise training is capable of increasing expression
of ABC transporters including ABCA-1 (Ghanbari-Niaki, Khabazian, Hossaini-Kakhak,
Rahbarizadeh, & Hedayati, 2007; Ghanbari-Niaki, Saghebjoo, & Hedayati, 2010;
Khabazian, et al., 2009) and MRP-1(Krause, et al., 2007). Khabazian, et al., (2009)
reported that exercise-induced increases in ABCA-1 expression were present in adult
male Wistar rats 2 days following a 12 week treadmill training protocol. In addition,
Ghanbari-Niaki, et al., (2007) reported significantly increased ABCA-1 expression in rats
24 hours post the completion of a 6 week treadmill training protocol when compared to
sedentary controls. This suggests that upregulation of ABCA-1 may be an adaptation to
increased endurance exercise. However, Ghanbari-Niaki, et al., (2010) recently reported
increased ABCA-1 mRNA expression in female students who completed a single session
of circuit-resistance training but the exercise-induced expression was observed in
lymphocytes not cardiomyocytes. Furthermore, Krause et al. (2007) reported rats that
performed 60 minutes of swimming exercise for 1 week displayed a significant increase
in MRP-1 expression (2.4-fold increase) which translated into a significant increase in
pumping activity, possibly suggesting that less DOX would reside in cardiomyocytes if
MRP-1/GS-X pumps were upregulated. The current investigation did not measure
ABCA-1 or MRP-1 expression; therefore, the relationship between the aforementioned
ABC transporters and DOX accumulation in myocardial cells remains unclear. However,
it is conceivable to speculate that exercise caused an upregulation of ABC transporters in
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TM+DOX and WR+DOX rat hearts which resulted in greater DOX extrusion and less
accumulation in the cardiac cell.
It has also been hypothesized that the accumulation of xenobiotics in target or
non-target tissues is primarily dependent on a mechanical barrier which influences the
intracellular concentration of the drug (Davin-Regli, et al., 2008). In a study by
Versantvoort (1992), multidrug resistant cells were altered to examine DAUN
accumulation and membrane permeability. A 5-fold efflux of DAUN was observed in
multidrug resistant cells lacking p-glycoproteins compared to controls suggesting other
mechanisms influenced DAUN accumulation in the MDR cells. Thus, it is probable that
the accumulation of DOX, in cardiomyocytes, depends not only on the drug efflux, but
also DOX influx across the cellular membrane (Han & Zhang, 2004). Further study is
necessary to examine the effects of exercise on ABCA-1 and MRP-1 expression and
determine if induction translates into less DOX accumulation, and a preservation of
cardiac function from DOX-mediated cardiotoxicity.
Due to the large number of samples per experimental subgroup, DOX
concentrations measured during the course of this experiment allowed for greater
statistical confidence in the obtained results. DOX accumulation was reduced in all
experimental groups over the course of 9 days. This finding is consistent with recent
DOX pharmacokinetic studies (Ahmed, et al., 2009; Staples, et al., 2010; Urva, et al.,
2009). DOX accumulation was not detected beyond 7 days of DOX exposure. Recently,
Staples, et al., (2010) reported that DOX was still present in rat heart 7 days post
treatment but could not be detected 8 days post using HPLC.
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In the present study, understanding the distribution of DOX in cardiac tissue over
time was also of interest. It is conceivable that greater DOX exposure (time or
concentration) to cardiomyocytes would result in greater cardiac insult. While a
reduction over time was as hypothesized, the degree of decline was unknown. The
SED+DOX (day 3) group displayed a 31% reduction in accumulation from SED+DOX
(day 1), a 63% reduction was observed in SED+DOX (day 5) compared to SED+DOX
(day 3), and a 45% reduction was observed in SED+DOX (day 7) when compared to
SED+DOX (day 5). The TM+DOX (day 3) group displayed a 47% reduction compared
to TM+DOX (day 1), a 62% reduction was observed in TM+DOX (day 5) compared to
TM+DOX (day 3), and no DOX was detected after 7 days post treatment. Similarly,
WR+DOX displayed a 47% clearance from day 1 to day 3, a 62% clearance from day 3
to day 5, and 100% clearance from day 5 to day 7. At the 9 day time point, DOX was not
detected in any of the exercised groups. It appears that the degree of decline, indicated
by percent change from one time point to another, was not drastically influenced by the
modality of exercise training. DOX metabolism was not measured in the current
investigation. However, it is plausible that exercise training resulted in elevated drug
metabolism immediately following exposure. After i.v. injection in rats and humans
(Rousseau & Marquet, 2002), DOX has a distributive half-life of about 5 minutes and a
terminal half-life of 20 to 48 hours (Danesi, Fogli, Gennari, Conte, & Del Tacca, 2002).
This suggests that DOX uptake by the tissues happens rapidly, while tissue elimination is
much slower. DOX is rapidly cleared from the plasma and extensively excreted through
the biliary pathway following injection (Danesi, et al., 2002; Salvatorelli, et al., 2009). It
has been reported that approximately 40% of DOX is excreted in bile and around 5-12%
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in the urine over the course of 5 days (Danesi, et al., 2002). It is plausible that the initial
uptake of DOX in LV tissue of exercise trained rats is reduced due to the upregulation of
MRP-1, resulting in a greater concentration of DOX in the plasma and reduced
concentration in the tissue.
Doxorubicin Metabolism
Another possible explanation for the reduction of DOX accumulation observed in
exercise trained rats is altered drug metabolism. DOX-induced cardiotoxicity occurs
following exposure of the parent drug and its metabolites (Sacco, et al., 2003).
Cytoplasmic aldo/keto or carbonyl reductases convert DOX to DOX-ol (Minotti, et al.,
2001). Doxorubicin is composed of an aglycone (doxorubicinone) and a sugar
(daunosamine). Doxorubicinone is a tetracyclic ring system with quinone-hydroquinone
moieties and a side chain with a carbonyl group at C-13. One-electron reduction of the
DOX quinone moiety is followed by redox cycling of oxygen and formation of ROS,
while a 2-electron reduction of the side-chain carbonyl group results in DOX-ol
formation (Minotti, et al., 2000; Sacco, et al., 2003). It has been suggested that the
secondary alcohol metabolite, DOX-ol, is associated with increased cardiotoxicity. In a
study by Olson et al., (1988) DOX-ol exhibited greater acute cardiotoxicity than the
parent drug DOX evidenced by reduced systolic function and impaired Ca++ handling.
Additionally, an investigation with overexpression of carbonyl reductases in transgenic
mice resulted in an increased conversion of DOX to DOX-ol and advanced the
development of cardiomyopathy (Forrest, Gonzalez, Tseng, Li, & Mann, 2000).
Furthermore, levels of DOX-ol in the heart have a greater correlation to cardiac
dysfunction than DOX (Sacco, et al., 2003). Investigators have suggested that the
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relationship between the secondary metabolites and cardiotoxicity may be due, in part, to
the fact that DOX-ol is more polar than DOX and subsequently more likely to accumulate
in the heart (Forrest, et al., 2000; Minotti, Recalcati, et al., 2004; Sacco, et al., 2003).
Collectively, these studies have demonstrated that increased DOX metabolism and/or
DOX-ol formation is related to heart damage suggesting the important role of
cytoplasmic reductases.
Evidence, though minimal, has linked exercise training to a reduction in reductase
enzyme expression which may explain its cardioprotective effects. Exercise has been
reported to alter the expression of cytoplasmic reductases. Following 30 minutes of
exercise, Aldo-keto reductase family 1, member-3, gene expression was down-regulated
5 fold (Connolly, et al., 2004). Similarly, in a recent study by Lee et al., (2011) it was
reported that exercise training down-regulates Nrf-2, a gene primarily responsible for the
coding of NAD(P)H quinone oxidoreductase. NAD(P)H quinone oxidoreductase is a
sub-family protein to oxidoreductases which are included in the carbonyl reductase
family. Furthermore, it has been reported that lower levels of carbonyl reductases results
in less conversion of DOX to DOX-ol in carbonyl reductase family 1 (cbr1 +/-) knockout
mice. Knockout mice (cbr1 +/-) were protected from DOX-cardiotoxicity compared to
cbr1 +/+ suggesting that a reduction of carbonyl reductase resulted in less DOX-ol
formation (Olson, et al., 2003).
The current investigation did not measure the expression of cytoplasmic reductase
enzymes; therefore, the relationship between exercise and DOX metabolism in
cardiomyocytes is unknown. However, reductases play a significant role in metabolizing
DOX and increasing the cardiotoxic properties of the drug. Thus, it is conceivable to
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speculate that TM+DOX and WR+DOX groups produced less secondary alcohol
metabolites than SED+DOX.
Secondary Cardioprotective Mechanisms
Other reports have shown that the protective effects of exercise against DOX
cardiotoxicity are associated with increased antioxidant enzyme upregulation (Ascensao,
Magalhaes, et al., 2005b; Chicco, Hydock, et al., 2006), a preservation of SERCA2a
expression (Lien, et al., 2009), and maintenance of cardiomyocyte ultrastructure
evidenced by decreased serum cardiac troponin I (Ascensao, Ferreira, Oliveira, &
Magalhaes, 2006). Other reports have shown exercise is associated with a preservation
of myosin heavy chain isoform expression (Hydock, Wonders, et al., 2009), decreased
lipid peroxidation (Wonders, et al., 2009), upregulation of HSP (Chicco, et al., 2005;
Chicco, Schneider, et al., 2006), and the attenuation of DOX-mediated increases in
caspase activity (Wonders, et al., 2009). It is likely that the aforementioned exercisemediated cardioprotecive mechanisms may be explained, in part, by the underlying
mechanism of reduced DOX accumulation in the left ventricular tissue of the exercised
animals.
A large amount of evidence indicates that ischemia-reperfusion and DOXmediated cardiac dysfunction are primarily mediated by oxidative stress (Abdel-Wahab,
et al., 2003; Kalyanaraman, et al., 2002; Kumar, Kirshenbaum, Li, Danelisen, & Singal,
2001; Patel, Joseph, Corcoran, & Ray, 2010; Sarvazyan, 1996). In the DOX-induced
cardiac dysfunction model, it is believed that the elevated myocardial oxidative stress is
mainly due to increased production of RONS as a result of DOX redox cycling (Minotti,
Recalcati, et al., 2004). The enhancement of SOD (Yen, et al., 1996) and endothelial
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nitric oxide synthase (Kalyanaraman, et al., 2002) status has been shown to lessen the
oxidative state, thus protecting the heart from DOX toxicity. In addition to DOXmediated cardiotoxicity, oxidative stress appears to play a key role in another cardiac
dysfunction model, ischemia reperfusion injury (Lennon, et al., 2004; Starnes, Taylor, &
Park, 2003). Prior studies have reported that antioxidant supplementation resulted in
cardioprotection from ischemia reperfusion injury (Coombes, et al., 2000; Hamilton, et
al., 2003; Powers, DeRuisseau, Quindry, & Hamilton, 2004). Therefore, in both models,
a reduced oxidant production appears to provide the myocardium protection and
contributes to the attenuation of cardiac dysfunction.
Researchers commonly suggest that the cardioprotective effect of exercise is due,
in part, to reduced production of ROS and increased antioxidant capacity (Ascensao,
Ferreira, & Magalhaes, 2007; Powers, Quindry, et al., 2004). Analysis of the oxidative
status was not conducted in the present study; thus, the degree of myocardial oxidative
stress due to DOX treatment is not known. However, it is plausible that a reduction in
DOX accumulation mediated by exercise training reduced the amount of DOX-mediated
RONS. Gunduz, et al., (2004) suggested that exercise is capable of inducing the
enhancement of other antioxidant defenses including GPx and CAT. In a study by
Kanter et al., (1985) mice were exercise preconditioned for 9 weeks prior to DOX
treatment. Interestingly, GPx and CAT activities were significantly increased in the
trained rats and offered protection from DOX-induced toxicity evidenced by histological
evaluation of the heart.
In contrast to primary antioxidant enzymes, it has been suggested that the
myocardium intrinsically protects itself from oxidative stress via antioxidant enzymes
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including thioredoxin (Berndt, Lillig, & Holmgren, 2007; Holmgren & Lu, 2010) and
peroxiredoxin (Kumar, Kitaeff, Hampton, Cannell, & Winterbourn, 2009). A review by
Berndt, et al., (2007) noted the potential cardioprotective role of thioredoxin and
thioredoxin reductase and suggested that these enzymes protect against oxidative stress
and inhibit apoptotic signaling. Similarly, peroxiredoxin has been reported to reduce
oxidative stress in the hearts of ischemically injured mice (Kumar, et al., 2009).
Therefore, in addition to the primary antioxidant enzymes associated with
cardioprotection it appears the heart may have other oxidative defenses. Currently, the
effect of exercise training on thioredoxin and peroxiredoxin in the heart is unknown.
However, Lappalainen, et al., (2009) reported that 8 weeks of exercise training increased
brain thioredoxin in male rats. Thus, it is plausible that exercise-induced changes in one
or all of these antioxidant systems may contribute to the preservation of cardiac function.
In addition to antioxidant defense, another explanation for the observed preservation of
cardiac function in exercise trained rats could be due to an attenuation of mitochondrial
dysfunction.
Mitochondria play a vital role in the synthesis of ATP. From a bioenergetic
standpoint, it is imperative that the mitochondria synthesize enough ATP to match the
cellular demand. When ATP synthesis is insufficient, metabolic demand is not met and
cellular death may occur (Baines, 2009b; Crompton, 1999). Under normal physiological
conditions, oxidative phosphorylation of acetyl coenzyme A (CoA), derived from the
beta oxidation of fatty acyl-CoA found inside the mitochondrial matrix, is primarily
responsible for meeting the cellular demand for ATP. The rate of ATP synthesis is
controlled largely by oxidative enzymes. Heart failure is associated with a reduction in
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key regulatory oxidative enzymes including acyl-CoA dehydrogenase and carnitine
translocase (Baines, 2009a; Kelly & Strauss, 1994; Roschinger, et al., 2000). De Sousa,
et al., (2002), reported that a downregulation in oxidative enzymes exacerbated the shift
from beta oxidation to glycolysis, suggesting an association between heart failure and
reduced fatty acid metabolism. Pellieux et al., (2006) overexpressed angiotensinogen in
transgenic mice to induce congestive heart failure and reported that fatty acid oxidation
was compromised. Recently, evidence has shown that in vitro, rat cardiomyocytes
exposed to angiotensin II, a modulator in heart failure, reduced fatty acid oxidation
(Pellieux, Montessuit, Papageorgiou, & Lerch, 2009). A reduction in fatty acid
metabolism may lead to mitochondrial dysfunction (van Bilsen, van Nieuwenhoven, &
van der Vusse, 2009). However, it was reported that 8 weeks of voluntary wheel running
exercise attenuated the observed metabolic shift in aortic banded rats (De Sousa, et al.,
2002). Furthermore, free carnitine, was reported to be increased in exercised trained rats,
thus contributing to increased fatty acid metabolism (Cha, Kim, & Daily, 2003). In aortic
banded pigs, low-intensity interval exercise training inhibited mitochondrial dysfunction
and preserved LV function (Emter & Baines, 2010). The aforementioned effects may
play an important role in the maintenance of mitochondrial biogenetics, improving its
resistance to ischemic or chemical induced dysfunction.
In addition to ATP deprivation, the production of ROS in mitochondria can lead
to mitochondrial dysfunction (Carvalho, et al., 2010; Lumini-Oliveira, et al., 2009; Zhou,
et al., 2001). Mitochondrial impairment following either ischemia reperfusion injury
(Baines, 2009a) or DOX treatment contributes to cardiac dysfunction (Ascensao, et al.,
2007; Ascensao, Lumini-Oliveira, Oliveira, & Magalhaes, 2011). An increased oxidative
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state can impair mitochondrial calcium homeostasis (Solem, et al., 1994) and ATP
synthesis which contributes to the opening of MPTP (Baines, 2009b). Starnes et al.,
(2007) reported that ROS production was elevated in myocardial mitochondria and
resulted in less calcium influx following ischemia reperfusion. Additionally, Marcil et al.
(2006) reported that mitochondria isolated from rat hearts exposed to anoxiareoxygenation injury in vitro resulted in calcium-induced MPTP opening. Similar to
reperfusion injury models, DOX treatment results in increased mitochondrial oxidative
stress due to heavy redox cycling which occurs at complex I (Tokarska-Schlattner, et al.,
2006; Wallace, 2003). It is believed that mitochondrial calcium homeostasis and MPTP
impairment is the result of an increased oxidative state (Baines, 2009b; Crompton, 1999).
Additionally, the intercalation of DOX into mtDNA may also contribute to mitochondrial
dysfunction. DOX and other DNA intercalators were reported to intercalate mtDNA and
caused mtDNA depletion in myocardial cells (Ashley & Poulton, 2009a). An in vitro
study by Sarvazyan (1996) indicated that a time-dependent accumulation of DOX
occurred in the mitochondria of cardiomyocytes. Thus, it appears that DOX has a high
affinity for mitochondria and DOX-induced mitochondrial dysfunction facilitates
destructive events in cardiomyocytes that may contribute to cardiac dysfunction.
Interestingly, numerous studies have reported that exercise preconditioning results
in cardiac mitochondrial adaptations that result in reduced ROS production (Kavazis,
Smuder, Min, Tumer, & Powers, 2010; Starnes, et al., 2007) and MPTP formation (Emter
& Baines, 2010; Kavazis, et al., 2010; Lumini-Oliveira, et al., 2010; Marcil, Bourduas,
Ascah, & Burelle, 2006). In the current investigation, cardioprotection was evident;
however, mitochondrial function was not determined. It is plausible, though, that the
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reduced DOX accumulation observed in the exercise trained groups resulted in less
DOX-mediated mitochondrial dysfunction, thereby providing a theoretical basis for the
observed preservation of cardiac function. Further study is needed to explore the
physiological significance of any interaction between physical activity and DOX
accumulation on mitochondrial dependent ROS, ATP synthesis, calcium homeostasis,
and MPTP opening in cardiomyocytes.
Summary and Conclusions
In the current investigation, DOX treatment resulted in acute cardiotoxicity.
Impaired systolic and diastolic cardiac function was observed both in vivo and ex vivo.
However, 10 weeks of exercise preconditioning resulted in a preservation of cardiac
function. Additionally, HPLC was successfully used to quantify DOX accumulation in
LV tissue of female rats at multiple time points. Voluntary wheel running activity or
involuntary treadmill exercise performed prior to DOX treatment resulted in less LV
DOX accumulation. This is believed to be the first study to investigate the
cardioprotective mechanism of exercise-mediated DOX accumulation. These findings
suggest that regular physical activity may be a valuable complementary therapy to offset
cardiotoxicities that often occur in cancer patients receiving DOX treatment.
Furthermore, cancer survivors participating in exercise training programs may be able to
better tolerate drug exposure, resulting in greater survival and an improvement in their
quality of life.
Limitations and Future Study
Based on the results of the current investigation, the following are limitations of
this study and recommendations for future research.
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1) This study employed the chemotherapeutic agent DOX to cancer-free rats to
investigate the effects of exercise, DOX, and time on cardiac function and DOX
accumulation. This investigation confirmed that exercise can reduce DOX accumulation
in the LV. Using a tumor-bearing animal model would be of interest to determine the
effect of exercise on DOX accumulation in tumor cells. Furthermore, future studies
could use a tumor-bearing model to confirm the results of this investigation and
additionally determine whether exercise affects the efficacy of this antineoplastic agent.
2) In this study, 10 weeks of either involuntary or voluntary exercise
preconditioning reduced LV DOX accumulation and preserved cardiac function in female
rats. In addition to chronic exercise preconditioning, short term exercise has also been
reported to be cardioprotective against DOX cardiotoxicity (Jensen, et al., 2009; Kavazis,
et al., 2010). Thus, the possibility exists that short term exercise may also result in
decreased DOX accumulation and preservation of cardiac function. Future study is
needed to determine the effect of short term exercise on DOX accumulation and cardiac
function.
3) Using the described HPLC based method, DOX accumulation was successfully
quantified in the LV of female rats. However, DOX metabolites such as DOX-ol,
aglycone-DOX, and aglycone-DOXol were not quantified. Evidence suggests DOX
metabolites are cardiotoxic and may have an even greater contribution to DOX-mediated
cardiotoxicity (Minotti, Menna, et al., 2004). Therefore, it would be of great interest to
investigate the effect of exercise on the accumulation of DOX metabolites.
4) In this study, the protective effects of exercise were associated with a reduction
in DOX accumulation. Recent evidence shows that ABC transporters such as MRP-1 are
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responsible for the cellular efflux of DOX (Dong, et al., 2009; Krause, et al., 2007; Shen,
et al., 2008; Zhang, et al., 2009). In future studies, it may be of interest to determine if
treadmill or wheel running exercise preconditioning effects the expression and/or activity
of MRP-1, thereby contributing to the exercise-induced extrusion of DOX from cardiac
cells.
5) In the current investigation, measurement of DOX accumulation was limited to
the heart to determine a cardiotoxic relationship. Exercise resulted in reduction of DOX
accumulation and preservation of cardiac function. However, DOX is known to cause
toxicity in other tissues including kidney (Ray, Patel, Wong, & Bagchi, 2000), lung
(Baciewicz, et al., 1991; Ray, et al., 2000) and liver (Mostafa, Mima, Ohnishi, & Mori,
2000). In future studies, it may be of interest to determine if exercise effects
accumulation in other tissues including the liver, kidney, lung and skeletal muscle.
6) Using HPLC, DOX accumulation was measured at 5 different time points over
the course of 9 days in sedentary and exercise preconditioned rats. However,
pharmacokinetic parameters such as the area under the concentration-time curve, plasma
clearance, distributive half-life, and volume of distribution were not included. The
aforementioned pharmacokinetic parameters can be used to describe the movement of
DOX throughout the body (Ahmed, et al., 2009; Staples, et al., 2010; Urva, et al., 2009).
Future study is needed to determine the effect of exercise on these parameters thus
allowing for the acquired data to then be compared to other pharmacokinetic models of
typical behavior.
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Raw Data
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Doppler mitral blood flow.
Group

Day

N

M-VTI (cm)

M-Vmax (cm/s)

M-Vmean (cm/s)

SED+SAL

1

9

3.63 ± 0.12

91.85 ± 4.78

63.93 ± 2.94

SED+DOX

1

10

3.51 ± 0.17

78.30 ± 1.99*

54.07 ± 2.94*

3

8

2.89 ± 0.21*

60.83 ± 4.37*

42.33 ± 3.24*

5

7

2.75 ± 0.16*

73.48 ± 8.62*

48.10 ± 5.49*

7

11

2.77 ± 0.20*

62.64 ± 4.68*

37.00 ± 4.36*

9

13

2.72 ± 0.13*

55.62 ± 2.90*

32.38 ± 2.63*

1

12

3.43 ± 0.11

85.69 ± 5.01

63.14 ± 3.88

3

13

3.89 ± 0.14

94.77 ± 4.04

64.82 ± 2.36

5

10

3.19 ± 0.22

93.23 ± 3.44

68.87 ± 3.46

7

10

3.25 ± 0.12*

87.17 ± 6.15

64.37 ± 4.66

9

6

3.29 ± 0.13*

100.11 ± 4.77

69.28 ± 3.03

1

10

3.59 ± 0.16

84.70 ± 4.66

64.47 ± 3.32

3

6

3.68 ± 0.18

96.00 ± 6.93

66.22 ± 4.21

5

10

3.29 ± 0.11*

92.77 ± 4.91

65.67 ± 3.17

7

8

3.38 ± 0.12

82.33 ± 4.37

59.54 ± 3.51

9

7

3.34 ± 0.16

84.90 ± 7.03

57.43 ± 5.96

TM+DOX

WR+DOX

Values are M ± SEM
SED+SAL, n = 9; SED+DOX, n = 49; TM+DOX, n = 51; WR+DOX, n =
41
M-VTI = Mitral velocity time integral
M-Vmax = Mitral maximal flow velocity
M-Vmean = Mitral mean flow velocity
* significant difference from SED+SAL
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Doppler aortic blood flow.
Group

Day N

A-VTI (cm)

A-Vmax (cm/s)

A-Vmean (cm/s)

SED+SAL

1

9

2.90 ± 0.16

98.15 ± 2.95

56.07 ± 1.59

SED+DOX

1

10

2.54 ± 0.17

80.47 ± 4.52*

47.33 ± 2.78*

3

8

2.10 ± 0.23*

67.71 ± 5.80*

42.00 ± 2.95*

5

6

2.74 ± 0.23

64.67 ± 4.57*

40.06 ± 2.07*

7

10

2.21 ± 0.19*

58.90 ± 4.15*

34.93 ± 2.23*

9

12

2.81 ± 0.32

62.33 ± 5.52*

36.78 ± 3.01*

1

12

2.50 ± 0.09*

84.11 ± 3.65

50.53 ± 2.08

3

13

3.24 ± 0.21

91.49 ± 5.46

57.44 ± 2.84

5

10

2.97 ± 0.14

103.50 ± 7.06

61.70 ± 3.74

7

10

3.20 ± 0.15

96.67 ± 5.19

60.00 ± 2.74

9

6

3.36 ± 0.26

93.56 ± 4.12

59.72 ± 2.68

1

10

2.63 ± 0.13

94.37 ± 3.96

56.07 ± 2.30

3

6

3.04 ± 0.26

86.39 ± 3.54

53.83 ± 2.49

5

10

3.28 ± 0.14

94.27 ± 3.14

57.00 ± 2.71

7

8

3.13 ± 0.28

83.29 ± 5.02

49.42 ± 2.79

9

6

3.21 ± 0.25

87.17 ± 6.48

54.00 ± 3.10

TM+DOX

WR+DOX

Values are M ± SEM
SED+SAL, n = 9; SED+DOX, n = 46; TM+DOX, n = 51; WR+DOX, n =
40
A-VTI = Aortic velocity time integral
A-Vmax = Aortic maximal flow velocity
A-Vmean = Aortic mean flow velocity
* significant difference from SED+SAL
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M-mode echocardiography.
Day

N

FS (%)

SED+SAL

1

5

67.13 ± 3.11

SED+DOX

1

11

56.50 ± 3.25*

3

6

52.39 ± 1.79*

5

5

56.48 ± 5.91*

7

8

50.95 ± 2.72*

9

8

50.47 ± 2.77*

1

13

65.01 ± 1.73

3

13

67.45 ± 2.69

5

9

59.43 ± 3.39

7

8

60.20 ± 3.86

9

4

61.60 ± 7.28

1

10

63.87 ± 3.03

3

9

62.25 ± 2.83

5

9

60.41 ± 2.46

7

7

58.49 ± 2.09

9

7

58.32 ± 4.33

Group

TM+DOX

WR+DOX

Values are M ± SEM
SED+SAL, n = 5; SED+DOX, n = 38; TM+DOX, n = 47; WR+DOX, n =
42
FS = Fractional shortening
* significant difference from SED+SAL
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Unpaced ex vivo cardiac function.
Group

Day N

ESP

EDP

LVDP

dP/dtmax

dP/dtmin

SED+SAL

1

9

97.99 ± 2.61

0.51 ± 0.76

97.48 ± 2.53

2851.24 ± 99.46

-2154.38 ± 60.62

SED+DOX

1

13

101.76 ± 4.34

0.01 ± 0.48

101.74 ± 4.14

2894.12 ± 291.5

-2118.03 ± 331.6

3

12

91.75 ± 4.41

2.56 ± 0.45

89.18 ± 4.30

2723.99 ± 131.6

-2134.89 ± 161.8

5

11

85.85 ± 4.37*

1.25 ± 0.47

84.6 ± 4.65* 2567.01 ± 125.6*

-1961.95 ± 82.03*

7

11

81.88 ± 6.66*

0.45 ± 0.82

81.43 ± 7.16*

2583.38 ± 245.7

-2077.90 ± 231.8

9

14

61.35 ± 2.95*

0.62 ± 0.44

60.73 ± 2.93* 1954.08 ± 66.98*

-1523.75 ± 57.23*

1

13 110.52 ± 3.32* -1.55 ± 0.44*

112.06 ± 3.3* 3209.14 ± 82.37*

-2565.22 ± 98.99*

3

12

103.56 ± 5.25

6.22 ± 0.49*

97.34 ± 4.83

2676.29 ± 100.6

-2115.69 ± 91.31

5

10

100.91 ± 5.94

2.58 ± 1.01

98.33 ± 6.05

2826.56 ± 181.6

-2262.07 ± 160.8

7

13

86.66 ± 3.15*

2.12 ± 0.60

84.54 ± 3.15*

2652.29 ± 120.0

-1942.06 ± 78.17*

9

10

88.21 ± 3.63*

-0.40 ± 0.67

88.61 ± 3.98* 2517.73 ± 83.00*

-1958.84 ± 55.03*

1

10 110.82 ± 3.49*

TM+DOX

WR+DOX

3.47 ± 0.47* 107.35 ± 3.46*

2799.00 ± 90.02

-2368.80 ± 65.85*

3

9

98.25 ± 3.01

1.75 ± 0.90

96.50 ± 3.46

2713.57 ± 146.8

-2089.58 ± 108.2

5

12

90.00 ± 4.26

0.81 ± 0.40

89.19 ± 4.19 2543.63 ± 110.9*

-2017.32 ± 83.82

7

10

95.81 ± 4.90

-0.17 ± 0.37

95.98 ± 5.00

2882.18 ± 150.4

-2268.48 ± 131.9

9

10

81.45 ± 2.35*

-0.87 ± 0.91

82.32 ± 1.69* 2376.79 ± 58.70*

-1891.85 ± 64.20*

Values are M ± SEM
SED+SAL, n = 9; SED+DOX, n = 61; TM+DOX, n = 58; WR+DOX, n = 51
ESP = End systolic pressure
EDP = End diastolic pressure
LVDP = Left ventricular developed pressure
dP/dtmax = Maximal rate of pressure developed
dP/dtmin = Maximal rate of pressure decline
* significant difference from SED+SAL
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Paced ex vivo cardiac function.
Group

Day N

ESP

EDP

LVDP

dP/dtmax

dP/dtmin

SED+SAL

1

9

112.13 ± 3.15

1.75 ± 0.85 110.38 ± 2.81

3450.68 ± 101.1 -2574.30 ± 118.2

SED+DOX

1

13

98.74 ± 3.15*

1.21 ± 0.57 97.52 ± 3.24*

3033.15 ± 276.1 -2264.74 ± 140.6

3

12

94.49 ± 3.86*

3.08 ± 0.42 91.42 ± 3.93* 2952.32 ± 101.4* -2292.44 ± 155.4

5

11

82.18 ± 3.32*

1.76 ± 0.33 80.42 ± 3.44* 2691.47 ± 74.36* -2021.69 ± 69.69*

7

11

85.91 ± 5.60*

1.45 ± 0.77 84.46 ± 5.97* 2861.01 ± 176.5* -2066.68 ± 130.5*

9

14

71.49 ± 3.37*

1.03 ± 0.57 70.46 ± 3.28* 2401.42 ± 99.03* -1803.16 ± 85.10*

1

13

109.04 ± 1.91 -0.89 ± 0.47* 109.93 ± 1.87

3

12

106.18 ± 4.52

5

10

105.84 ± 5.79

2.88 ± 0.96 102.96 ± 5.98

7

13

92.17 ± 5.05*

2.59 ± 0.62 89.58 ± 5.00* 3009.52 ± 160.8* -2233.95 ± 160.7

9

10

94.20 ± 3.42*

0.37 ± 0.67 93.83 ± 3.76* 2997.16 ± 121.1* -2139.66 ± 64.65*

1

10

111.56 ± 3.75

3

9

96.34 ± 1.37*

2.05 ± 0.72 94.29 ± 1.54* 2935.78 ± 95.73* -2270.70 ± 71.68*

5

12

99.47 ± 4.74*

1.25 ± 0.31 98.23 ± 4.64* 3029.98 ± 160.2* -2357.55 ± 148.0

7

10 104.24 ± 4.74*

9

10

TM+DOX

WR+DOX

90.60 ± 2.34*

3402.00 ± 78.50 -2751.75 ± 87.07

6.49 ± 0.66* 99.69 ± 4.17* 2960.59 ± 111.7* -2202.45 ± 85.87*

4.28 ± 0.52* 107.28 ± 3.72

-0.11 ± 0.28 104.34 ± 4.66

3298.98 ± 300.9 -2405.33 ± 165.5

3279.88 ± 108.9 -2566.07 ± 114.6

3343.82 ± 164.1 -2616.42 ± 149.5

0.99 ± 0.90 89.61 ± 2.47* 2993.21 ± 149.9* -2068.54 ± 80.99*

Values are M ± SEM
SED+SAL, n = 9; SED+DOX, n = 61; TM+DOX, n = 58; WR+DOX, n = 51
ESP = End systolic pressure
EDP = End diastolic pressure
LVDP = Left ventricular developed pressure
dP/dtmax = Maximal rate of pressure developed
dP/dtmin = Maximal rate of pressure decline
* significant difference from SED+SAL
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Left ventricular DOX accumulation.
Day
SED+DOX
TM+DOX
WR+DOX
(ng DOX/g LV)
(ng DOX/g LV)
(ng DOX/g LV)
*
a
1
702.16 ± 24.90
416.88 ± 42.89
525.68 ± 30.61a
3
484.49 ± 36.14*
219.64 ± 21.61a
173.25 ± 11.57 a
*
a
83.94 ± 17.19
54.67 ± 7.82 a
5
178.15 ± 21.09
N/D a
N/D a
7
97.37 ± 24.59*
9
N/D
N/D
N/D
Values are M ± SEM
SED+DOX, n = 65; TM+DOX, n = 61; WR+DOX, n = 61
N/D = Not detectable
*
Significant difference between groups (p < 0.001)
a
Significantly less than SED+DOX (p < 0.05)
No significant differences were observed between TM+DOX and WR+DOX (p >
0.05)
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